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ABSTRACT 
Somatic stem cells are the basic tools of regenerative medicine and gene therapy, 
providing unique opportunities for the therapy of genetic and acquired disorders. 
The molecular mechanisms underlying fundamental characteristics of human 
somatic stem cells, such as self-renewal, commitment and differentiation, are still 
poorly understood. A better knowledge of these mechanisms is crucial to the 
understanding of stem cell biology and to the development of stem cell-based 
therapies. High-throughput approaches, such as next-generation sequencing 
technologies (NGS) became fundamental to study the transcriptome, the 
epigenome and the usage of regulatory elements in the genome. Genome-wide 
approaches allow investigating the molecular circuitry wiring the genetic and 
epigenetic programs of human somatic stem cells. Here, we define the 
transcriptional and epigenetic profile of human hematopoietic stem/progenitor cells 
(HSPC) and early myeloid and erythroid progenitors through an integrative 
analysis of Cap Analysis of Gene Expression (CAGE) and chromatin immuno-
precipitation (ChIP-seq) data, in order to identify transcription regulatory elements 
that act in HSPC lineage commitment. CAGE analysis enabled us to define more 
than 10,000 active promoters in HSPCs and in erythroid (EPP) and myeloid 
precursors (MPP). The different cell types shared most of the promoters, with only 
a small fraction (about 4%) being differentially transcribed, suggesting that the 
transcriptional state is largely maintained in early hematopoietic progenitors and 
precursors. Interestingly about 30% of the identified of cell-specific promoters was 
not annotated. These novel transcripts are possibly involved in HSPCs self-
renewal, commitment and differentiation. To obtain a genome-wide description of 
the transcriptional regulatory regions in multipotent and lineage-restricted 
hematopoietic progenitors, we performed ChIP-seq analysis for histone 
methylations typical of promoters and enhancers, H3K4me3 and H3K4me1, 
respectively, and for H3K27ac to mark the active elements. Overall we identified 
more than 20,000 active enhancers that consistently changed upon erythroid and 
myeloid commitment: about 80 and 95% of the active enhancers mapped in HSPC 
disappeared in erytrhoid and myeloid progenitors, respectively, while novel 
enhancers are acquired during lineage commitment. These data indicate that 
enhancers are dramatically redefined during lineage commitment, and that 
differential enhancer usage is responsible for the differential regulation of promoter 
activity underlying lineage restriction. This study provided an overview of the 
differential transcriptional programs of HSPCs and committed myeloid and 
erythroid hematopoietic precursors and represents a unique source of genes and 
regulatory regions involved in self-renewal, commitment and differentiation of 
human hematopoietic stem/progenitor cells and their progeny. 
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SOMMARIO'
Le cellule staminali somatiche rappresentano uno strumento chiave della medicina 
rigenerativa, aprendo opportunità importanti per la terapia di patologie ereditarie e 
acquisite. I meccanismi molecolari alla base delle cellule staminali somatiche 
umane, come l’autorinnovamento, il commitment e il differenziamento sono ancora 
oggetto di studio. Una migliore conoscenza di questi meccanismi è fondamentale 
per la comprensione della biologia delle cellule staminali e per lo sviluppo di 
terapie basate su di esse. Metodologie ad alta performanza (high-throughput), 
come il sequenziamento di ultima generazione (NGS, next generation sequencing) 
sono alla base degli studi di trascrittomica, epigenomica e per l’annotazione degli 
elementi regolatori della trascrizione genica. In questo lavoro abbiamo definito il 
profilo trascrizionale ed epigenetico delle cellule Staminali/Progenitrici 
Ematopoietiche (HSPC, hematopoietic/progenitor cells) e della loro progenie 
eritroide (EPP) e mieloide (MPP), attraverso analisi integrative di dati da 
esperimenti di Cap Analysis of Gene Expression (CAGE) e immunoprecipitazione 
della cromatina accoppiata a sequenziamento ultramassivo (ChIP-seq), al fine di 
identificare gli elementi di regolazione genica responsabili del commitment delle 
HSPC. L’analisi CAGE ha permesso di identificare più di 10,000 promotori attivi in 
HSPC, EPP e MPP. I tre tipi cellulari condividono più del 90 dei promotori attivi e 
solo una piccola parte risulta differenzialmente espressa. Il 30% dei promotori 
identificati con CAGE risulta non annotato, suggerendo che i trascritti originate da 
essi possano rivestire un ruolo chiave nell’autorinnovamento, commitment e 
differenziamento delle HSPC. Al fine di ottenere una mappa delle regioni 
regolatorie, abbiamo messo ap punto analisi ChIP-seq su modificazioni istoniche 
tipiche di promotori ed enhancers, come H3K4me3 e H3K4me1, e note per 
marcare regioni attive del genoma, come H3K27ac. Complessivamente abbiamo 
identificato più di 20,000 enhancers attivi che cambiano in modo consistente 
durante il commitment eritroide e mieloide, dimostrando che circa il 80 e il 90% 
degli enhancers attivi in HSPC non è più presente nella progenie, mentre nuovi 
enhancers vengono aquisiti da EPP e MPP. Questi dati indicano che gli enhancers 
sono profondamente ridefiniti durante il commitment e che l’utilizzo differenziale di 
questi elementi regolatori è resonsabile della regolazione differenziale dei 
promotori durante questa fase. Questo studio costituisce una risorsa importante 
per lo studio dei programmi trascrizionali che coinvolgono le HSPC, in quanto 
riporta una collezione esaustiva dei geni e delle regioni regolatrici coinvolte nel 
commitment di queste cellule.  
! iii!
TABLE OF CONTENTS 
1. Introduction .................................................................................. 1 
1.1. The epigenome ................................................................................ 2 
1.1.1. The structure of the chromatin .................................................... 2 
1.1.2. Post-translational histone modifications ..................................... 3 
1.1.3. Chromatin immunoprecipitation sequencing (ChIP-seq) ............ 6 
1.2. The transcriptome ......................................................................... 10 
1.2.1.The study of the transcriptome through Cap Analysis of Gene 
Expression (CAGE) sequencing ......................................................... 11 
1.3. Transcriptional regulatory elements ........................................... 14 
1.3.1. Promoters ................................................................................. 14 
1.3.2. Distal regulatory elements ........................................................ 16 
1.3.2.1. Enhancers ...................................................................................... 16 
1.3.2.2. Silencers, insulators and LCRs. .................................................... 17 
1.4. Hematopoiesis ............................................................................... 20 
1.4.1. The classical model of hematopoiesis ...................................... 20 
1.4.2. The hematopoietic stem cell ..................................................... 22 
1.4.2.1. Phenotypic characterization of HSCs ............................................ 24 
1.4.2.2. Molecular regulation of HSC formation and self renewal .............. 24 
1.4.2.3. Molecular regulation of lineage commitment ................................. 26 
1.4.2.4. Chromatin landscapes in HSC differentiation ................................ 28 
1.5. Aim of the work ............................................................................. 30 
2. Materials and methods .............................................................. 31 
2.1. Cell types ....................................................................................... 31 
2.1.1. Hematopoietic stem/progenitor cells (HSPCs) ......................... 31 
2.1.2. Erythroid progenitors (EPPs) .................................................... 31 
2.1.3. Myeloid progenitors (MPPs) ..................................................... 32 
2.1.4. CFU assay ................................................................................ 32 
2.1.5. Gene expression profiling ......................................................... 32 
2.2. ChIP-seq ......................................................................................... 33 
2.2.1. ChIP assay ............................................................................... 33 
2.2.2. ChIP-seq library preparation and sequencing .......................... 33 
2.2.3. Bioinformatic data analysis ....................................................... 33 
2.2.4. Identification of cis-regulatory elements ................................... 34 
2.3. CAGE .............................................................................................. 35 
2.3.1. Library preparation, sequencing and mapping ......................... 35 
2.3.2. Promoter construction .............................................................. 35 
2.3.3. Promoter annotation ................................................................. 36 
! iv!
2.3.4. Statistical analysis .................................................................... 36 
3. Results and Discussion ............................................................ 37 
3.1. Purification and characterization of multipotent and lineage-
restricted hematopoietic progenitors ................................................ 37 
3.2. Characterization of regulatory elements usage in HSPC and 
lineage-restricted progenitors ............................................................ 41 
3.2.1. Genome-wide histone modification profiling by ChIP sequencing
 ............................................................................................................ 41 
3.2.1.1. Identification of histone modifications enriched regions ................ 45 
3.2.2. Identification of regulatory elements ......................................... 46 
3.2.2.1. Definition of promoters and enhancers by ChIP-seq data 
integration ................................................................................................... 47 
3.2.2.2. Comparative analysis of active cis-regulatory elements in HSPC, 
EPP and MPP ............................................................................................. 49 
3.3. Transcriptomic analysis of HSPC during lineage commitment 54 
3.3.1. Definition of whole genome high resolution map of transcription 
initiation events by CAGE sequencing ............................................... 55 
3.3.1.1 CAGE sequencing mapping statistics and single nucleotide 
resolution annotation .................................................................................. 55 
3.3.1.2. Promoters identification and annotation from CAGE-seq data ...... 56 
3.3.2. Quantitative transcriptomic analysis of HSPC and lineage-
restricted progenitors .......................................................................... 57 
3.3.2.1. Differential expression analysis of CAGE promoters ..................... 57 
3.4. Chromatin dynamics at cis-regulatory elements ....................... 64 
4. Conclusions and Perspectives ................................................. 66 
5. References .................................................................................. 69 
6. APPENDIX ................................................................................... 79 
6.1. Antibodies used for FACS analysis. ............................................ 79 
6.2. Differentially expressed genes in erythroid commitment detected 
using arrays. ....................................................................................... 79 
6.3. Differentially expressed genes in myeloid commitment. .............. 87 
6.4. Lists of promoters ........................................................................ 90 
6.5. Lists of active enhancers ............................................................. 90 
!  
! v!
LIST OF FIGURES AND TABLES 
Figure 1. Characteristics of epigenomes. 5 
Figure 2. Transcriptional regulatory elements in metazoans. 14 
Figure 3. Hierarchy of hematopoiesis. 22 
Figure 4. Purification and characterization of multipotent and lineage-restricted 
hematopoietic progenitors 38 
Figure 5. CFC assay. 39 
Figure 6. Check for sufficient sequencing depth. 43 
Figure 7. Cross-correlation profiles. 44 
Figure 8. Histone mark enrichment at transcription start sites. 45 
Figure 9. Dynamics of promoter and enhancer chromatin signatures upon HSPC 
commitment. 49 
Figure 10. Example of identified enhancer regions at human beta globin locus. 50 
Figure 11. Genomic distribution of CAGE TSSs in HSPC, EPP and MPP. 55 
Figure 12. Annotation of total and differentially used CAGE promoters. 56 
Figure 13. Genomic distribution of CAGE promoters in repetitive elements. 57 
Figure 14. Functional annotation of genes associated to cell-specific promoter 59 
Figure 15. Example of alternative promoter usage. 61 
Figure 16. Analysis of putative TFBS within CAGE promoters. 62 
Figure 17. Distribution of total and differentially used unannotated CAGE 
promoters overlapping with epigenetically defined  
 promoters and enhancers. 63 
Figure 18. Effect of H3K27ac on nearest neighbor genes. 63 
Figure 19. Histone modification average enrichments at differentially expressed 
promoters. 64 
Figure 20. Histone modification average profile at lineage-specific active 
enhancers. 65 
 
Table 1. Sequencing data and QC statistics. 42 
Table 2. Statistics of histone modifications enriched regions. 46 
Table 3. Statistics of all promoters and enhancers identified by ChIP-seq data 
integration. 48 
Table 4. Statistics of H3K27ac+ promoters and enhancers identified by ChIP-seq 
data integration. 48 
Table 5. Analysis of TFBS in epigenetically defined enhancers. 54 
Table 6. Statistics of promoters identified by CAGE TSSs clustering. 56 
! vi!
ABBREVIATIONS 
CAGE: Cap Analysis of Gene Expression 
ChIP: Chromatin ImmunoPrecipitation 
CLP: Common Lymphoid Precursor 
CMP: Common Myeloid Precursor 
CRE: Cis Regulatory Element 
DEG: Differentially Expressed Genes 
EPP: Erythroid Progenitor 
FRiP: Fraction of Reads in Peaks 
HM: Histone Modification 
HSPC: Hematopoietic Stem/Progenitor Cell 
IP: ImmunoPrecipitation 
MPP: Myeloid Progenitor 
NGS: Next-Generation Sequencing 
PTM: Post-Translational Modification 
TF: Transcription Factor 
TSS: Transcription Start Site   
! 1!
1.'INTRODUCTION'
The completion of human genome sequence project opened new 
challenges in understanding how the information encoded in DNA directs 
the specification, development, and fate of hundreds of different cell types. 
The accurate realization of biological processes, such as proliferation, 
apoptosis, aging and differentiation, requires, in fact, a precise and 
coordinated execution of series of steps that depend on the proper 
expression of the human genome. The deregulation of these processes 
results in abnormal phenotypes and eventually in disease.  
Currently, in the era of genomics and personalized medicine, a complete 
and quantitative catalogue of genome features and expression profiles of 
every cell type is required to understand the fundamental mechanisms that 
control cellular processes. Despite intensive studies our understanding of 
the genome is far from being complete. Therefore the complete analysis of 
regulatory sequences, and of the mechanisms that regulate genome 
transcription, is essential and is a mandatory requirement to fully 
understand genome organization, and ultimately cell biology, in both 
physiological and pathological states. 
In the recent years the development of high-throughput approaches, mainly 
based on next-generation sequencing (NGS) technologies, pushed forward 
genetic studies to a genome-wide scale. The technological advancement 
raised the need of proper informatics methodologies to manage, analyse 
and integrate the huge amount of data produced by genomic experiments. 
In this framework bioinformatics and computational biology became fields 
of striking importance in genomic research, for which one of the main goals 
is the identification of the complete collection of epigenetic modifications of 
DNA sequences and chromatin (the epigenome), transcripts (the 
transcriptome) and the functional elements that regulate gene expression 
of a specific cell type. Each individual aspect offers a unique and 
complementary view of genome organization and cellular function: 
integrating them together offers the huge potential to answer many long-
standing biological questions. 
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1.1.'The'epigenome'
An important emerging area of biological research concerns the packaging 
of DNA into chromatin and, specifically, how cell type-specific chromatin 
organization enables differential access to and activity of regulatory 
elements and the manifestation of unique cellular phenotypes.  
1.1.1.'The'structure'of'the'chromatin'
The genomic DNA in the eukaryotic cell nucleus is hierarchically packaged 
with proteins to form chromatin. The eukaryotic chromatin can be viewed 
as a highly organized dynamical structure in which the primary structure, 
the DNA-protein polymer, is folded and compacted into three-dimensional 
chromatin fibres of increasing sizes to form the eukaryotic chromosome. 
The smallest repeating unit of chromatin is the nucleosome, which is 
composed by ~147 base pairs of DNA forming a two-turn helix around a 
compact histone octamer core consisting of two copies of histones H2A, 
H2B, H3 and H4. The core histone proteins are composed of structured 
globular domains that mediate the interaction with the DNA, and a flexible 
relatively unstructured N-terminal tails that extend away from nucleosomal 
surface. A consequence of the DNA wrapping around the histone core is 
the sterical occlusion of other DNA-binding proteins thus regulating their 
access to the DNA. Nucleosomes are connected by short DNA segments 
(linker DNA, ~10–80 bp in length) into nucleosomal arrays, which undergo 
short-range interactions with neighbouring nucleosomes to form chromatin 
fibres [1]. This beads-on-a-string organization of individual nucleosomes is 
termed chromatin primary structure. Despite the high ordered structure, the 
nucleosomes are not static but partially unwrap and rewrap spontaneously. 
This nucleosome property is crucial to regulate occupancy of DNA-binding 
proteins in a tunable manner through different mechanisms that can 
modulate the nucleosome stability and dynamics, including DNA 
modifications, post-translational modifications of histones (PTMs), 
incorporation of histone variants, ATP-dependent chromatin remodeling 
and non-coding RNA-mediated pathways. All these changes are epigenetic 
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modifications, which are heritable changes that do not involve variations in 
DNA sequence; they regulate chromatin structure and DNA accessibility, 
and influence how the genome is made manifest across a diverse array of 
developmental stages, tissue types, and disease states. The epigenome is 
defined as the combination of all epigenetic modifications in any given cell 
type, including DNA methylation, post-translational histone modifications 
and histone variants. Complex organisms such as humans do not have a 
single epigenome, but instead have multiple epigenome depending on the 
tissue type and developmental stage. So the epigenome is not static like 
the genome, but it can be dynamic, influenced by environmental factors 
and extracellular stimuli, and change in response to these factors. 
Deregulation of these epigenetic events has been observed in various 
cancers and human diseases.  
1.1.2.'Post@translational'histone'modifications'
Histone proteins are subject to a number of covalent modifications, such as 
methylation, acetylation, phosphorylation, ubiquitylation and ADP-
ribosylation, which can occur at many sites. There are over 60 different 
residues on histones where modifications have been detected either by 
specific antibodies or by mass spectrometry, but this value may represent 
an underestimation of the total number of modifications that can take place 
on histones. This vast array of modifications gives enormous potential for 
functional responses, but it has to be remembered that not all these 
modifications will be on the same histone at the same time. The timing of 
the appearance of a modification will depend on the signalling conditions 
within the cell [2]. PTMs of histones occur on either within the globular core 
or on the amino-terminal tails of core histones and can act in two ways: i) 
directly affecting the chromatin compaction and assembly or ii) serving as 
binding sites for effector protein [3]. In the first case, histone modifications 
may affect higher-order chromatin structure by modifying the contact 
between different histones in adjacent nucleosomes or the interaction of 
histones with DNA. In the second case, depending on the composition of 
modifications on a given histone, a set of proteins, such as chromatin 
remodelers and transcription factors involved in different processes (e.g. 
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transcription initiation, elongation) are encouraged to bind or are occluded 
from chromatin. One of the most well studied PTMs is the acetylation of 
lysine residues of histones, an highly dynamic process regulated by two 
class of enzymes, histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). The HATs catalyse the transfer of an acetyl group 
to the lysine side chains, neutralizing the lysine’s positive charge with the 
consequence of disruption of the electrostatic interactions between 
histones and DNA, therefore facilitating the DNA access to transcription 
machinery. This function correlates with their role of transcriptional 
coactivators. HDACs enzymes reverse the effect of HATs and restore the 
positive charge of the lysine residues, stabilizing the local chromatin 
architecture thus acting mainly as chromatin repressors. The other 
important class of histone modifications is the methylation, which mainly 
occurs on the side chains of lysines and arginines. Unlike acetylation, this 
class of PTMs does not alter the charge of histone proteins but it has a 
higher level of complexity because lysine residues can be mono-, di-, tri-
methylated and arginine can be mono-, symmetrically or asymmetrically di-
methylated, with different consequences on chromatin dynamics. This 
characteristic of methylation is supported by the existence of relatively 
specific classes of enzymes, such as histone lysine methyltransferases 
(KMTs) that methylate distinct lysine residues (e.g. H3K4, lysine 4 on 
histone 3) to a specific degree (mono-, di- or tri-methylation) [4]. 
Methylation of histones is implicated in multiple cellular processes, 
depending on the residue being methylated and on the degree of 
methylation. Methylation of five residues within the N-terminal tail (H3K4, 
H3K9, H3K27, H3K36 and H4K20) of histones H3 and H4, and of two 
residues in the globular domain (H3K64 and H3K79) of histone H3 have 
been functionally characterized. In general, H3K9, H3K27, H3K64 and 
H4K20 methylation have been implicated in transcriptional silencing, 
whereas H3K4, H3K36 and H3K79 methylation are associated with 
transcriptionally active regions [5]. However, depending on the methylation 
states and the genomic location the same modification might have different 
functional outcomes. H3K9 methylation is involved in euchromatic gene 
silencing as well as in heterocromatin formation [6, 7] while H3K27 
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methylation has an important role in the repression of genes during 
development [8] (Figure 1).  
 
'
Noncoding RNA. Studies in Schizosaccharomyces pombe 
have shown that small RNAs that function as interfering 
RNAs can target and maintain heterochromatin132,133 
(also, see REF. 134 for a recent review). A recent study 
used ChIP–chip to map regions of heterochromatin 
and euchromatin as well as RNAi components and 
small interfering RNAs (siRNAs) across the S. pombe 
genome135. This study confirmed the interdependence 
of RNAi and heterochromatin on a genomic scale. 
Furthermore, recent studies in humans have shown 
that ncRNAs are involved in demarcating active and 
silent chromatin domains136.
Protein binding in relation to chromatin modifications. 
Several techniques discussed in this Review have been 
used to profile the chromatin occupancy of various 
chromatin or DNA-binding proteins (for a recent review 
see REF. 137). The utility of ChIP–chip was originally 
demonstrated by identifying Gal4 and Ste12 binding 
sites in the yeast genome7. The extension of ChIP–chip 
to ChIP–Seq has recently been used to identify binding 
sites for REST (RE1-silencing transcription factor; also 
known as neuron restrictive silencer factor)18, STAT1 
(signal transducer and activator of transcription 1)19 and 
CTCF (CCCTC-binding factor)17, an insulator-binding 
protein, in the human genome.
Another technique — DNA adenine methyltrans-
ferase ID (DamID) — has also been used to identify 
DNA-binding sites on a genomic scale. In this tech-
nique, DNA-binding proteins are first fused to DNA 
adenine methyltransferase (Dam). When the protein 
of interest is expressed in a cell, Dam is targeted to the 
binding sites of this protein where it methylates local 
adenine bases. This local methylation can be detected 
to determine the binding sites of the protein of interest. 
DamID has been used to identify binding sites of HP1 
(heterochromatic protein 1) in the D. melanogaster 
genome138.
An epigenomic picture
Technical progress in genome-wide mapping 
approaches during the past few years has enabled the 
examination of various epigenetic phenomena at a glo-
bal level in various model organisms. Consequently, 
a comprehensive picture of epigenomes is emerging 
(FIG. 5). DNA is methylated throughout the genome 
except at functional regulatory regions, which include 
promoters and enhancers. Large heterochromatin 
domains are associated with widespread H3K9me2 and 
H3K9me3 signals as well as HP1 binding139. Conversely, 
euchromatic domains are associated with localized 
signals of H3K4me as well as H2A.Z and H3.3, occur-
ring mainly at functional regulatory regions such as 
promoters, enhancers and insulators. These functional 
regulatory elements are characterized by DNase I 
hypersensitivity, and active promoters are depleted 
of nucleosomes. The monomethylation of H2BK5, 
H3K9, H3K27 and H4K20 as well as H3K36me3 are 
associated with actively transcribed regions, whereas 
H3K27me3 is widespread across silent genes in 
euchromatic domains.
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Figure 5 | Characteristics of epigenomes. The interaction of DNA methylation, 
histone modification, nucleosome positioning and other factors such as small RNAs 
contribute to an overall epigenome that regulates gene expression and allows  
cells to remember their identity. Chromosomes are divided into accessible regions  
of euchromatin and poorly accessible regions of heterochromatin. Heterochromatic 
regions are marked with histone H3 lysine 9 di- and trimethylation (H3K9me2 and 
H3K9me3), which serve as a platform for HP1 (heterochromatic protein 1) binding. 
Small RNAs have been implicated in the maintenance of heterochromatin. DNA 
methylation is persistent throughout genomes, and is missing only in regions such as 
CpG islands, promoters and possibly enhancers. The H3K27me3 modification is 
present in broad domains that encompass inactive genes. Histone modifications 
including H3K4me3, H3K4me2, H3K4me1 as well as histone acetylation and histone 
variant H2A.Z mark the transcription start site regions of active genes. The 
monomethylations of H3K4, H3K9, H3K27, H4K20 and H2BK5 mark actively 
transcribed regions, peaking near the 5a end of genes. The trimethylation of H3K36 
also marks actively transcribed regions, but peaks near the 3a end of genes.
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Figure 1. Characteristics f epigenomes. The interaction of DNA methylation, histone 
modification, nucleosome positioning and other factors such as small RNAs contribute to 
an overall epigenome that regulates gene expression and allows cells to reme ber their 
identity. Histone modific tions including H3K4me3, H3K4me2, H3K4me1 as well as 
histone acetylation and histone variant H2A.Z mark the transcription start site regions of 
active genes. Th  H3K27me3 modificatio  is present in broad domains that encompass 
inactive genes. The mono ethylati ns of H3K4, H3 9, H3K27, H4K20 and H2BK5 mark 
actively transcribed regions, peaking near the 5′ end of genes. [9] 
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1.1.3.'Chromatin'immunoprecipitation'sequencing'(ChIP@seq)'
Genome-wide mapping of protein–DNA interactions and epigenetic marks 
is essential for a full understanding of transcriptional regulation. The main 
tool for investigating these mechanisms is chromatin immunoprecipitation 
(ChIP), which is a technique for assaying protein–DNA binding in vivo. In a 
ChIP-seq experiment, DNA fragments associated with a specific protein are 
first enriched. The DNA-binding protein is cross-linked to DNA in-vivo by 
treating cells with formaldehyde and the chromatin is sheared by sonication 
into small fragments, which are generally in the 200-600 bp in range. An 
antibody specific to the protein of interest is used to immunoprecipitate the 
DNA-protein complex. Finally, the crosslinks are reversed and the released 
DNA is assayed to determine the sequences bound by the protein. During 
the construction of a sequencing library, the immunoprecipitated DNA is 
subject to size selection (typically in the ~150-300 bp range, although there 
seems to be a bias towards shorter fragments in sequencing). The 
experimental steps in ChIP involve several potential sources of artefacts. 
Shearing of DNA, for example, does not result in uniform fragmentation of 
the genome: open chromatin regions tend to be fragmented more easily 
than closed regions, which creates an uneven distribution of sequence tags 
across the genome. Moreover, repetitive sequences might seem to be 
enriched because of inaccuracies in the number of copies of the repeats in 
the assembled genome. Also, ChIP-seq presents a bias in fragment 
selection towards GC-rich content, both in library preparation and in 
amplification before and during sequencing. For these reasons a peak in 
the ChIP–seq profile should be compared with the same region in a 
matched control sample to determine its significance. There are three 
commonly used types of control sample: input DNA (a portion of the DNA 
sample removed prior to immunoprecipitation (IP)), mock IP DNA (DNA 
obtained from IP without antibodies), and DNA from nonspecific IP (IP 
performed using an antibody, such as immunoglobulin G, against a protein 
that is not known to be involved in DNA binding or chromatin modification). 
To obtain accurate estimates throughout the genome, sufficient numbers of 
tags are needed at each point; otherwise fold enrichment at the peaks will 
result in large errors due to sampling bias. When an insufficient number of 
! 7!
reads is generated, there is a loss of sensitivity or specificity in detection of 
enriched regions. Thus effective analysis of ChIP-seq data requires 
sufficient coverage by sequence reads (sequencing depth). The required 
depth depends mainly on the size of the genome and the number and size 
of the binding sites of the proteins. In order to assess the sequencing 
depth, is has been suggested to progressively downsample the amount of 
reads of each sample and compute the fraction of peaks that are recovered 
respect to the total number of peaks called using the whole sample 
(saturation analysis). In this way it is possible to evaluate if depth e of 
sequencing has already reached a saturation point (plateau) or if it is 
necessary to sequence more the sequencing libraries. A typical workflow 
for the computational analysis of ChIP-seq data consist in the following 
steps: i) read mapping and quality assessment; ii) identification of 
statistically enriched regions (peak calling); iii) downstream integrative 
analysis. In the first step, before mapping the reads to the references 
genome, a quality cut-off has to be applied to filter out low quality 
sequences. Sometimes, after this step is necessary trim the end of low-
quality reads. The remaining reads should then be mapped using one of 
the available mappers such as Bowtie [10] or BWA [11], accounting for a 
proper number of mismatches relative to the read lengths and discarding 
reads that map in multiple sites in genome, in order to retain as much 
informative reads as possible and avoiding introduction of noise [12]. One 
of the first steps in quality controls after read mapping is the check of the 
library complexity that is the measure of how the library is representative of 
the binding patterns along the genome. This step is performed viewing the 
read alignments on an appropriate genome browser (e.g. IGV) and 
measuring the fraction of nonredundant reads over the total mapped reads.  
Ideally each fragment of the sequencing library should represent an 
immunoprecipitation event of the binding protein of interest in a 
homogenous cell population. In case of low complexity, the library 
fragments are likely to be clonal, thus the sequencing steps start to 
resample continuously the same genomic loci, resulting in clonal reads. 
The low library complexity is linked to many factors such as antibody 
quality, over-cross-linking, amount of materials, sonication, or over-
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amplification by PCR. After sequenced reads are aligned to the genome, 
the next step is to identify regions that are enriched in the ChIP sample 
relative to the control with statistical significance. Several peak-calling 
algorithms that scan the genome to identify enriched regions are currently 
available. These algorithms take the advantage of the directionality of the 
reads. The fragments are sequenced at the 5' end and the locations of 
mapped reads should inferred from two distributions, one on the positive 
strand and the other on the negative strand, with a consistent distance 
between the peaks of the distributions. In these methods, a smoothed 
profile of each strand is constructed and the combined profile is calculated 
either by shifting each distribution towards the center or by extending each 
mapped position into an appropriately oriented fragment and then adding 
the fragments together. Given a combined profile, peaks can be scored in 
several ways. A simple fold ratio between ChIP and Input DNA can provide 
important information, but it is not adequate because it does not take into 
account the depth of sequencing of the peak and the corresponding region 
in Input sample. To this end, statistical models (i.e. Poisson model or 
binomial model) that can take into account both parameters have been 
applied in peak calling algorithms A major difficulty in identifying enriched 
regions is that there are three types: sharp, broad and mixed. Sharp peaks 
are generally found for protein–DNA binding or histone modifications at 
regulatory elements, whereas broad regions are often associated with 
histone modifications that mark domains (e.g. transcribed or repressed 
regions). Tools such MACS [13] were developed to identify sharp peaks in 
contrast to SICER [14] that identify broader regions, while spp [12] was 
developed to identify peaks with mixed profiles. The statistical significance 
of enriched sites is generally measured by the false discovery rate (FDR) 
[15], which is the expected proportion of incorrectly identified sites (e.g. 
peaks identified in input sample) among those that are found to be 
significant. After obtaining high quality peaks, different approaches can be 
applied to analyse the biological implications of ChIP-seq data. One of the 
most common downstream analyses is the discovery of binding sequence 
motifs [16, 17], which allows the de novo discovery of binding motifs as well 
as the identification of known binding sites in broader regions, such as 
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H3K4me1 in enhancers. Another downstream analysis that can be 
performed using ChIP–seq data is to annotate the location of the peaks on 
the genome in relation to known genomic features, such as the 
transcriptional start site, exon–intron boundaries and the 3′ ends of genes. 
This analysis can be improved adding information about the expression 
levels of genes, to infer if the gene is a target of an activator, if a chromatin 
mark is enriched at the promoters of genes with high expression or if ChIP 
peaks are significantly enriched in a particular molecular function or 
biological process through Gene Ontology analysis [18, 19]. More 
advanced analysis includes the discovery of novel elements based on 
integration of different ChIP–seq data. In the last years, different 
bioinformatics tools have been designed to analyse ChIP-seq data and to 
characterize genome regulatory elements in both unsupervised (i.e. without 
prior information) and supervised ways, as Hidden Markov Models [20], 
dynamic Bayesian networks [21], profile methods [22] and intersection of 
enriched island [23]. However no standard method has been developed to 
detect cis-regulatory elements yet, due to different experimental design and 
to a lack of consensus on the rules to detect cis-regulatory modules. 
Overall, ChIP sequencing together with derived novel methods for 
downstream analysis, has become a principal tool for understanding 
transcriptional cascades and deciphering the information encoded in 
chromatin. 
! '
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1.2.'The'transcriptome'
A comprehensive understanding of biological networks is strictly dependent 
on the complete description of the cell transcriptome, that is the complete 
set of transcripts in a cell, and their quantity, for a specific developmental 
stage or physiological condition, which represents a key link between 
information encoded in DNA and phenotype. The classic image of a 
mammalian transcriptome is composed of a large assembly of spliced [24] 
mRNAs, each structured with a capped 5’ end, a 5’ untranslated region (5’ 
UTR), a coding sequence (CDS), a 3’ untranslated region (3’ UTR) and a 
poly-A tail. The sequencing project of human genome allowed the 
identification and the annotation of about 25,000 protein-coding genes [25]. 
The advances in high-throughput technologies currently challenge this view 
of mammalian transcriptome, which show an increase in complexity of the 
transcriptional output of cells. This complexity is reflected by the existence 
of alternative splice forms that may create functional diversity in protein 
isoforms presenting different domain combinations, the use of alternative 
gene starts and thereby potentially different regulatory mechanisms for 
different forms of the genes. In the last years different studies have shown 
that the mammalian genome is pervasively transcribed [26], which results 
in the active transcription of approximately 93% of the human genome [27]. 
Next generation sequencing technology, such as RNA-seq and CAGE-seq, 
have allowed the discovery of a broad range of ncRNAs as well as a huge 
number of genomic loci being transcribed. Recent studies have indeed 
highlighted the complexity of mammalian genome by revealing tens of 
thousands sites being transcribed to transcripts with little or no coding 
potential [28, 29]. The majority of transcripts identified do not encode for 
proteins and belonging to the class of noncoding RNAs (ncRNAs), like 
ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs). Moreover, the 
transcriptome seems to double its size when considering the set of 
transcripts not having a poly-A tail [30]. NcRNAs can be divided in different 
categories on the basis of their functions: structural ncRNAs, i.e. ribosomal, 
transfer, small nuclear and small nucleolar RNAs, regulatory ncRNAs, i.e. 
micro RNAs (miRNAs), small interference RNAs (siRNAs), and long 
noncoding RNAs (lncRNAs). MiRNAs are 22 nucleotide (nt) RNAs that bind 
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predominantly to the 3’ UTRs of mRNA, causing gene silencing; siRNAs 
are 21 nt long and also function in the degradation of complementary 
mRNAs; lncRNAs are transcribed RNA molecules greater than 200 nt in 
length that are implicated in post-transcriptional gene regulation through 
controlling protein synthesis, RNA maturation and transport, and also in 
transcriptional gene silencing through regulating the chromatin structure 
[31]. LncRNAs can be poly-A+ or poly-A-, are mainly located in the nucleus 
and can be classified accordingly to their placement respect to close 
protein coding genes as sense, antisense, bidirectional, intronic and 
intergenic [24]. Members of intergenic lncRNAs have been demonstrated to 
regulate epigenetic marks and thus gene expression [32, 33]. In addition, a 
novel class of RNAs transcribed at enhancers (eRNAs) has been described 
[34]. The size of eRNAs has been shown to range from 0.1 to 9 kb, with an 
average size of 800 nt [35], placing most of the eRNAs into a subgroup of 
lncRNAs. These transcripts elongate both bidirectionally or unidirectionally 
and can lead to the production of both poly A+ or poly A- transcripts; 
eRNAs have a short half-life and are positively correlated to levels of 
nearby mRNA expression, this suggests a possible functional role for 
eRNAs as transcriptional activators. 
1.2.1.The'study'of'the'transcriptome'through'Cap'Analysis'of'Gene'
Expression'(CAGE)'sequencing'
Various technologies have been developed to deduce and quantify the 
transcriptome, including hybridization or sequence-based approaches. 
Hybridization-based approaches on arrays have several limitations, such 
as the reliance upon existing knowledge about genome sequence, high 
background levels owing to cross-hybridization, and a limited dynamic 
range of detection owing to both background and saturation of signals. On 
the contrary, sequence-based approaches directly determine the cDNA 
sequence. In recent years several technologies have become available to 
sequence the DNA at a high throughput levels, and have been applied 
together with different protocols and methodologies to study the genome 
and the transcriptome. Among them a new high-throughput approach to 
gene expression analysis is Cap Analysis of Gene Expression (CAGE) [36], 
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that was introduced as method to determine transcription start sites on a 
genome-wide scale by isolating and sequencing short sequence tags 
originating from the 5’ end of RNA transcripts. Mapping these tags back to 
the reference Genome identifies the transcription start sites from which the 
transcripts originated. CAGE relies on a cap-trapper system to capture full-
length RNAs while avoiding rRNA and tRNA transcripts. First, an oligo-dT 
primer is used to reverse-transcribe poly-A terminated RNAs. Alternatively, 
a random primer can be used for RNAs without a poly-A tail, which may 
constitute almost half of the transcriptome. Subsequently, full-length cDNA 
are select by biotinylated cap-trapped their 5’ cap structure, allowing 
capture by streptavidin-coated magnetic beads. Ligation of a specific linker 
sequence containing an Mme1 recognition site to the 5’ end of the full-
length cDNA creates a restriction site about 20 nucleotides downstream, 
producing a short CAGE tag starting at the 5’ end of eukaryotic mRNAs. 
Then, 5’ ends tags (‘CAGE tags’) are isolated and after the cleavage, 
sequences tags are purified and sequenced. At high sequencing depths 
significantly expressed TSSs are typically sequenced a large number of 
times. It thus becomes possible to not only map the locations of TSSs but 
also quantify the expression level of each individual TSS, then CAGE it is a 
unique tool in the analysis of transcriptional regulatory networks. The first 
step in the analysis of deep-sequencing expression data is the mapping of 
the (short) reads to the genome from which they derive. CAGE tags are 
usually mapped to a reference genome using a novel alignment-algorithm 
called Kalign2 that maps tags in multiple passes [37]. Once the RNA 
sequence reads or CAGE tags have been mapped to the genome, the next 
step is to obtain a collection of positions for which at least one read/tag is 
present. In multiple samples it could be obtain, for each position, a read-
count or tag-count profile that counts the number of reads/tags from each 
sample, mapping to that position. These tag-count profiles quantify the 
expression. CAGE-tag based expression measurements directly link the 
expression to individual TSSs, thereby providing a optimal guidance for 
analysis of the regulation of transcription initiation. Large-scale sequence 
analysis, performed in the FANTOM3 project (http://fantom.gsc.riken.jp/), 
made clear that most genes are transcribed in different isoforms that use 
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different TSSs. Alternative TSSs not only involve initiation from different 
areas in the gene locus, but TSSs typically come in local clusters spanning 
regions ranging from a few to over 100 bps. Hence, these tag clusters are 
defined by a start and end position, have a count of tags and a distribution 
of these counts, and they are the representation of the promoters. An 
analysis of CAGE-defined TSSs in human and mouse accomplished by 
Carninci et al. [38], illustrate that tag clusters can be divided into different 
shape classes. The two main types identified are the single peak (SP) 
class, that is characterized by sharp peak, indicative of a single, well 
defined TSS, and the broad (BR) shape class, that is characterized by 
multiple, weakly defined TSSs. Other shape classes can be described as 
subtypes of the broad class or hybrids between broad and sharp class. 
Specifically, in single peak (SP) class promoters the majority of tags are 
concentrated to no more than four consecutive start positions, giving a 
single dominant TSS. This class of promoters is generally associated with 
TATA boxes. Importantly, only a minor fraction (<25%) of promoters belong 
to this class. Instead, the broad (BR) shape class promoters have broad 
distribution of TSSs generally spread over 100 nt. They are strongly 
associated with CpG islands and are GC rich. This study showed that more 
than half of protein coding transcriptional units had two or more alternative 
promoters, based on the presence of non-overlapping tag clusters. 
! '
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1.3.'Transcriptional'regulatory'elements'
The execution of biological processes such as development, proliferation, 
apoptosis, aging, and differentiation requires a precise and carefully 
orchestrated set of steps that depend on the proper spatial and temporal 
expression of genes. Interpretation of genomic information involves 
integration of cellular history and extracellular environment, which 
ultimately occurs at the level of chromatin and is mediated by the 
functionally diversified cis-regulatory elements, such as promoters, 
enhancers, silencers, and insulators (Figure 2).  
 
Figure 2. Transcriptional regulatory elements in metazoans. The promoter is 
typically comprised of proximal, core and downstream elements. Transcription of a 
gene can be regulated by multiple enhancers that are located distantly and 
interspersed with silencer and insulator elements. H3K4me1/2, histone H3 mono- or 
dimethylation at lysine 4; H3K4me3, histone H3 trimethylation at lysine 4; 
H3K27me3, histone H3 trimethylation at lysine 27; H3.3/H2A.Z, histone variants 
H3.3 and H2A.Z; LCR, locus control region; TATA, 5′-TATAAAA-3′ core DNA 
sequences; TSS, transcription start site. [39] 
 
1.3.1.'Promoters'
Gene core promoters are the regions overlapping transcription start sites 
(TSSs) of genes that serve as the docking sites for the basic transcriptional 
machinery, and define the position of the TSSs and the direction of 
transcription. Core promoters are generally characterized by the presence 
of multiple elements, which are recognized by different subunits of the 
preinitiation complex (PIC) [40]. The proximal promoter is defined as the 
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Figure 1 | Transcriptional egulatory el ments in metazoans. The promoter is typically comprised of proximal, 
core and downstream elements. Transcription of a gene can be regulated by multiple enhancers that are located 
distantly and interspersed with silencer and insulator elements, which are bound by regulatory proteins such as 
CCCTC-binding factor (CTCF). Recent genome-wide data have revealed that many enhancers can be defined  
by unique chromatin features and the binding of cyclic AMP-responsive element-binding (CREB) protein (CBP). 
H3K4me1/2, histone H3 mono- or dimethylation at lysine 4; H3K4me3, histone H3 trimethylation at lysine 4; H3K27me3, 
histone H3 trimethylation at lysine 27; H3.3/H2A.Z, histone variants H3.3 and H2A.Z; LCR, locus control region;  
TATA, 5′-TATAAAA-3′ core DNA sequences; TSS, transcription start site. Figure is modified, with permission, from REF. 97 
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together with cohesin, may have an active role in the con-
trol of transcripti n by stabilizing long-range enhancer–
promoter interactions13. The role of these interactions is 
not limited to the egulation of tr nscription initiat n; 
the interactions may also be required to release RNAPII 
from promoter-proximal pausing14. These findings are 
beginning to clarify the mechanisms by which enhancers 
can activate transcription over relatively long distances 
in an orientati -independent manner with the exquisite 
precision required to orchestrate the complex process of 
cell differentiation during development.
Chromatin features of enhancers
The distribution of post-translational histone modifica-
tions and the presence of specific histone variants influ-
ence gene expression by orchestrating the interaction of 
transcription factors with the chromatin fibre15. During 
the last few years, genome-wide mapping of epigeneti-
cally marked nucleosomes has been conducted in an 
attempt to understand how various histone modifica-
tions affect gene expression. These studies have led to 
new insights into the chromatin landscape of enhanc-
ers and its functional significance in the regulation of 
specific gene expression programmes.
Nucleosome dynamics define transcriptional enhancers. 
Assembly, mobilization and disassembly of nucleosomes 
can influence transcription and other processes that 
act on eukaryotic DNA16. Results from genome-wide 
mapping studies of nucleosome occupancy in different 
species indicate that the boundaries of cis-regulatory 
domains are marked by high rates of histone replace-
ment17, and transcription start sites are frequently 
associated with regions of low nucleosome occupancy 
(normally termed nucleosome-free regions)10,18–23. These 
findings suggest that nucleosome instability contributes 
to gene regulation by facilitating the access of transcrip-
tion factors to promoters and other regulatory elements. 
The presence of highly unstable nucleosomes contain-
ing the histone variants H3.3 and H2A.Z at several 
well-characterized enhancers suggests that nucleosome 
dynamics might also be important for their regulatory 
functions20,24,25 (FIG. 2). Indeed, this hypothesis is sup-
ported by three recent genome-wide studies. Isolation of 
HeLa cell chromatin with low salt concentration, which 
maintains the association of unstable histone variants 
to DNA, has led to the discovery that H3.3/H2A.Z-
containing nucleosome core particles are enriched at the 
nucleosome-free regions of regulatory elements across 
the genome26. Furthermore, regions of the genome that 
are hypersensitive to DNase I in CD4+ T cells but not 
in HeLa cells contain unstable double-variant nucleo-
somes in the CD4+ T cells but not the HeLa cells (FIG. 2a). 
This result indicates that the presence of dynamic nucleo-
somes reflects the activity of the hypersensitive sites, 
which in turn carry histone modifications correlated 
with enhancer activity20,26 (see below).
Analysis of androgen-mediated transcriptional pro-
grammes in prostate cancer cells has revealed a class of 
enhancers containing androgen receptor and forkhead 
box protein A1 (FOXA1) binding sites27. These enhanc-
ers are occupied by a central H2A.Z-containing nucleo-
some and a pair of flanking nucleosomes with histone 
H3 dimethylated at lysine 4 (H3K4me2). Androgen 
stimulation results in the disappearance of the central 
H2A.Z-containing nucleosome and an increase in the 
signal of the flanking H3K4me2 nucleosomes (FIG. 2b). 
This observation is indicative of transcription factors dis-
placing the nucleosome at their binding site. Quantitative 
modelling based on the behaviour of paired H3K4me2 
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region immediately upstream (up to a few hundred base pairs) from the 
core promoter, and typically contains multiple binding sites for activators 
that act synergistically on transcriptional regulation. 
RNA polymerase II (RNAPolII)-transcribed genes are highly heterogeneous 
with respect to expression level and context specificity and this is reflected 
by the existence of different architectures, which in turn determine the 
promoter functions and regulation types. In fact metazoan promoters can 
be divided in three main classes, depending on particular characteristics. 
Type I promoters are defined “sharp promoters” because exhibit a precise 
start site at which most transcription initiates. They have low frequency of 
CpG islands and possess a TATA box, an AT enriched sequence that is 
binding site for the TBP subunit of TFIID. These promoters are associated 
to tissue specific genes. H3K4me3 is generally present downstream of the 
TSS and there is no RNAPolII binding at these sites when genes are not 
expressed [41, 42]. Type II promoters are associated with ubiquitously 
expressed genes and usually possess a unique CpG island overlapping the 
TSS. These promoters are usually defined “broad promoters”, since they 
have dispersed TSS [43]. At these genes H3K4me3 histone mark 
distribution is almost identical with the span of CpG islands, overlapping the 
5’ end of the genes [44]. Type III promoters are sharper than type II 
promoters, are associated to developmental genes, and have multiple 
features associated with repression, such as large CpG island that extend 
in the gene bodies, binding of Polycomb group (PcG) proteins, and 
presence of both H3K4me3 and H3K27me3, associated with activation and 
repression, respectively [45]. Because of this last characteristic, these 
promoters are defined “bivalent promoters”. These three main classes of 
promoters are preferentially associated with different subset of epigenetic 
states. While tissue-specific genes (type I promoters) seem to depend 
mostly on cis-regulatory modules for regulation, and typically are active or 
inactive, the housekeeping genes (type II) have few enhancers in 
neighbouring regions and are generally characterized by active 
configuration. Developmental genes (type III) are regulated at both 
promoter and enhancer levels, have high number of enhancers associated, 
and have heterogeneous promoter states (e.g. poised and repressed 
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states) [20]. These types of promoters also show different pattern of 
nucleosome occupancy and positioning, reflecting the different 
mechanisms of regulation, to which they may be subjected. 
1.3.2.'Distal'regulatory'elements'
Temporal and tissue-specific gene expression in mammals depends 
primarily on distal regulatory elements (i.e., enhancers, silencers, 
insulators, and LCR), which are often located far away from the genes they 
control . 
1.3.2.1.%Enhancers%
Enhancers play a central role in driving cell-type-specific gene expression 
and are capable of activating transcription of their target genes at great 
distances, ranging from several to hundreds, in rare cases even thousands, 
of kilobases [46]. Recent advances in chromatin profiling methodologies 
have revealed more than 400,000 of these regulatory elements across 
several cell types [47], suggesting an enormous combinatorial complexity 
of expression patterns during human development. These distal elements 
are viewed as clusters of DNA sequences capable of binding combinations 
of transcription factors that then interact with components of the Mediator 
complex (TFIID) to help recruit RNAPolII, and can enhance transcription 
independent of their location, distance or orientation with respect to the 
promoters of genes [48]. However, it is not clear whether the enhancer-
mediated delivery of factors is predominantly required to initiate 
transcription and/or to continuously sustain gene expression. Among the 
enhancers-interacting protein factors, there are also histone modifying 
enzymes or ATP-dependent chromatin remodeling complexes that alter 
chromatin structure and increase the accessibility of the DNA to other 
proteins [49]. Enhancers can be associated with high dynamic 
nucleosomes with histone variants H3.3 and H2A.Z [50]. Nucleosomes 
directly flanking TF binding sites are less mobile and usually marked with 
H3K4me1 and H3K27ac, two modifications that have been extensively 
used to identify active enhancers in several studies [51]. H3K4me1 is also 
present at 5’ of actively transcribed promoters, but differentially from these, 
enhancers do not have H3K4me3 signature, because of the lack of CpG 
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islands at enhancers, which are preferentially recognized by CxxC domain 
of H3K4me3 methyltransferases complexes. This histone modification 
premarks enhancers prior to their deployment upon differentiation in 
different models, such as hematopoietic system; in fact the presence of 
H3K4me1 often precedes nucleosome depletion, deposition of H3K27ac, 
and enhancer activation [52, 53]. H3K4me1 is thought to block repressor 
protein binding, such as DNA methyltransferases or histone deacetylases, 
or as binding platform for specialized effector/coactivator proteins, such as 
histone acetyltransferases. Enhancers are indeed bound by p300 and CBP, 
two highly homologous HATs that has been used for genome-wide 
enhancer mapping in multiple cell types [54]. These proteins are recruited 
at enhancers by a broad range of sequence-dependent activator factors, 
and have H3K27 as main substrate [55]. Acetylated lysine residues are 
recognized by bromodomains, present in diverse nuclear proteins, 
including HATs themselves (e.g. p300, CBP, PCAF, and Gcn5), ATP-
dependent remodelers (e.g. BRG1), TFIID components, and factors 
regulating transcriptional pause release. Overall, histone acetylation 
directly affects enhancer function through attenuating nucleosomal stability, 
promoting chromatin decompaction and/or regulating enhancer-promoter 
communication. A large subclass of enhancers lacks H3K27ac end is 
enriched in H3K27me3 and bound by Polycomb complex PRC2. These 
regulatory elements are termed “poised enhancers” and are typically found 
near early developmental genes, which has bivalent promoters [53]. Poised 
enhancers show similar patterns of active enhancers (p300, BRG1, similar 
nucleosome depletion levels), except that are unable to drive gene 
expression until H3K4me3 is removed in favour of the gain of H3K27ac. 
1.3.2.2.%Silencers,%insulators%and%LCRs.%
Other regulatory DNA elements that contribute to the formation and 
maintenance of active or inactive transcription programs and play an 
integral part in gene regulation ere silencers, insulators and locus control 
regions (LCRs). 
Silencers are sequence-specific elements that confer a negative (i.e., 
silencing or repressing) effect on the transcription of a target gene. They 
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function independently of orientation and distance from the promoter and 
they can be located as part of a proximal promoter, as part of a distal 
enhancer, or as an independent distal regulatory module; in this regard, 
silencers can be located far from their target gene, in its intron, or in its 3’-
untranslated region. Silencers bind transcription repressors acting through 
inhibition of gene transcription. In some cases, repressors appear to 
function by blocking the binding of a nearby activator, or by directly 
competing for the same site. A repressor may prevent the general 
transcriptional machinery from accessing a promoter by establishing a 
repressive chromatin structure through the recruitment of histone-modifying 
activities or by inhibiting PIC assembly [56]. 
Insulators  (also known as boundary elements), function in a position-
dependent, orientation-independent manner to block genes from being 
affected by the transcriptional activity of neighbouring genes. They thus 
create boundaries in chromatin limiting the action of transcriptional 
regulatory elements into defined domains, and partition the genome into 
discrete domains of expression. There are two types of insulators: 
enhancer-blocking insulators, which prevent communication between 
discrete sequence elements (typically enhancers, or even silencer, and 
promoters) when positioned between them, and barrier insulators, which 
prevent the spread of heterochromatin. The core insulator fragment 
contains binding sites for several transcription factors; in vertebrates, the 
only known insulator protein is CCCTC-Binding Factor (CTCF) that is 
necessary for enhancer-blocking activity. It is proposed that CTCF creates 
distinct loop domains, in which the enhancer in one loop is unable to 
contact a promoter in a different loop [57, 58].  
Finally, developmental and cell lineage-specific regulation of gene 
expression relies upon Locus control regions (LCRs), that are groups of 
regulatory elements involved in regulating an entire locus or gene cluster. 
Locus control regions are operationally defined as elements that enhance 
the expression of linked genes to physiological levels in a tissue-specific, 
position-independent and copy-number- dependent manner. LCRs are 
often marked by a cluster of nearby DNase I hypersensitive sites (HS) and 
are thought to provide an open-chromatin domain for genes to which they 
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are linked. LCRs are typically composed of multiple cis-acting elements, 
including enhancers, silencers and insulators. These elements are bound 
by transcription factors (both tissue-specific and ubiquitous), coactivators, 
repressors, and/or chromatin modifiers. Each of the components 
differentially affects gene expression, and it is their collective activity that 
functionally defines a LCR and confers proper spatial/temporal gene 
expression. The final most prominent effect of the LCRs is a strong, 
transcription-enhancing activity. The identification of a large number of 
LCRs has revealed that, although LCRs are typically located upstream of 
their target gene(s), they can also be found within an intron of the gene 
they regulate, downstream of the gene, or even in the intron of a 
neighbouring gene [59].  
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1.4.'Hematopoiesis'
Hematopoiesis is a term used to describe the process of blood cell 
formation during both the embryonic and adult stages of an organism. 
Hematopoiesis is also viewed as the process of development, self-renewal 
and differentiation of hematopoietic stem cells (HSCs), a type of adult stem 
cell that is the source of all blood cell lineages.  
1.4.1.'The'classical'model'of'hematopoiesis' '
Hematopoiesis is usually depicted in a hierarchical way, with HSCs giving 
rise first to progenitors and then to precursors with varying commitments to 
multiple or single pathways. In this hierarchical schema hematopoietic cells 
can be broadly classified as transiting through three steps: stem cells, 
committed progenitor cells, and precursors of mature functional-end cells. 
Although this representation may oversimplify the hematopoietic process, it 
can provide a useful framework in which divide and classify the 
intermediate cells (Figure 3). 
At the top of this hierarchy, the stem cell compartment is composed of very 
rare cells with the ability to self-renew and differentiate into multilineage 
precursors. Lineage markers are absent from these cells, and they 
normally are found in a quiescent state or are turning over very slowly. 
Stem cells are also equipped with a regimen of critical transcription factors 
that are important in the execution of their fundamental cellular functions of 
cell renewal and multilineage differentiation.  
The progenitor cell compartment contains cells that are found at a higher 
frequency than the stem cell pool and, like the stem cell, are not 
morphologically distinguishable. Their existence is revealed by their ability 
to give rise to differentiated progeny in vitro in well-defined functional 
assays. The progenitor cell compartment is derived from stem cells through 
a process of commitment to different lineage pathways. Transition of stem 
cells to cells of the committed compartment is achieved not by acquisition 
of new characteristics or new proteins but by enhancement of certain 
molecular pathways, already primed in these cells, and abrogation of 
others. As progenitor cells differentiate, they acquire more distinctive 
features characteristic of each lineage and move away from shared 
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primitive progenitor characteristics: they show the enhancement of lineage-
specific features, with a diminished or absence of expression of 
multilineage properties. In this manner, precursors for the various lineages 
arise. 
The precursor cell compartment is defined by morphological criteria and 
contains cells at different maturation stages; these precursors can be 
further distinguished by cell-surface markers. Precursor cells for each 
lineage follow a unique maturation sequence. The morphological 
characteristics of these cells reflect the accumulation of lineage-specific 
proteins, and organelles and the decline of nuclear activity, which gives 
them a unique appearance.  
A cellular roadmap that specifies lineage relationships between stem, 
progenitor, precursor and mature cells is indispensable for a 
comprehensive view of the transcriptional and epigenetic mechanisms that 
control normal development. In this regard the first comprehensive 
‘‘classical’’ model of hematopoiesis was formulated. The first key postulate 
of this model is that loss of self-renewal capacity by HSCs during 
differentiation precedes lineage commitment. At this step multilineage 
progenitors (MP) remain multipotent, but possess only transient capacity of 
repopulation. The second postulate states that MPs segregate in the two 
branches of the hematopoiesis model: lymphoid and myeloid. This earliest 
myelo-lymphoid split gives rise to common myeloid progenitors (CMPs) and 
common lymphoid progenitors (CLPs) and each of these undergo further 
commitment steps. On the lymphoid side CLPs give rise to B cell 
precursors and the earliest thymic progenitors (ETPs) committed to the T 
and NK lineages, while on the myeloid one CMPs give rise to granulocyte 
macrophage progenitors (GMPs), which become committed to the 
granulocyte (neutrophils, eosinophils, mast cells, and basophils) and 
monocyte fates, and megakaryocyte-erythrocyte progenitors (MEPs), which 
will eventually produce erythroid and megakaryocyte cells. This classical 
model is a simple yet powerful template for understanding blood 
development and interpreting the function of molecular regulators. 
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1.4.2.'The'hematopoietic'stem'cell'
HSCs are defined in an operational sense as cells competent to 
reconstitute the entire haematopoietic system of an individual. HSCs are 
capable of self-renewal and differentiation in all cell types that constitute 
the blood tissue. These two processes are strongly dependent on the 
microenvironment in which HSCs reside. The production of these cells is 
accomplished by the allocation and specification of distinct embryonic cells 
in a variety of sites that change during development [61]. In mammals, the 
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Figure 4: Hierarchy of hematopoiesis. The phenotypic cell surface marker of each population of mouse and human blood system is
shown (modified from [13]). In the mouse hematopoiesis system, MPPs omit CMPs which directly give rise to MEPs unlink in the human
system (dash line). CLP, common lymphoid progenitor; CMP, common myeloid progenitor; DC, dendritic cell; EP, erythrocyte progenitor;
GMP, granulocyte/macrophage progenitor; GP, granulocyte progenitor; HSC, hematopoietic stem cell; MacP, macrophage progenitor; MEP,
megakaryocyte/erythrocyte progenitor; MkP, megakaryocyte progenitor; NK, natural killer; Lin, lineage markers.
expressing CD34+CD90+(Thy-1)Lin− which could give rise
to T and B lymphocytes and myeloerythroid activities in
both in vitro and in vivo human fetal thymus transplanted
into SCID mice while some subset of CD34−, CD90−,
Lin− lacked of multipotent progenitors [93]. Further
isolation of HSCs was based on the expression of CD38
[94, 95] and CD45RA [96]. This data could be concluded
that Lin−CD34+CD38−CD90+CD45RA− population en-
riches for human HSCs and the candidate human MPP
fraction of multipotency with an incomplete self-renewal
capacity is enriched in Lin−CD34+CD38−CD90−CD45RA−
population [97]. However, recently observation using
HSC xenograft assay in NOD-SCID-IL2Rgc−/− (NSG)
mice has shown tha both L n−CD34+CD38−CD90−
CD45RA− and Lin−CD34+CD38−CD90+CD45RA− contain
LT repopulating activity in secondary recipients with
diﬀerent frequency [98]. In addition, CD49f (integrin
α6) marker has been shown as a specific HSC marker
within Lin−CD34+CD38−CD45RA− population which as
single-sorted HSC is highly eﬃcient in generating long-term
multilineage graft while the loss of CD49f expression
results in the absence of long-term grafts [98]. Furthermore,
Rhodamine-123 marker (eﬄux of the mitochondrial
dye) is added to enrich for HSCs where high Rho eﬄux
(Rholo)Lin−CD34+CD38−CD90+CD45RA− can also repop-
ulate all blood lineages in secondary recipients [98]. Taken
together, these results demonstrate that human HSCs are
enriched in the Lin−CD34+CD38−CD90+/−CD45RA−Rholo
population of hematopoietic cells (Figure 4).
5. Signaling Pathways in Self-Renewal
andMaintenance of HSCs
The balance that controls between self-renewal and dif-
feren iation (or cell fate decision) of HSC in the bone
marrow is mediated by several factors. There are a number
of animal models promoting the concept that the niches
inside bone marrow provide the maintenance and regulation
of HSCs by some microenvironmental-dependent signals.
Most HSCs are in quiescent state (i.e., in G0/G1 phase of
the cell cycle) [99], however, when the hematopoietic cells
disturbance occurs, hematopoiesis system will respond by
shutting down or turning on the regulators mediated in the
Figure 3. Hierarchy of ematopoiesis. The phenotypic ell surfac  marker of each 
population of mouse and human blood system is shown. In the mouse hematopoiesis 
system, MPPs omit CMPs which directly give rise to MEPs unlink in the human 
system (dashed line). CLP, common lymphoid progenitor; CMP, common myeloid 
progenitor; DC, dendritic cell; EP, erythrocyte progenitor; GMP, granulocyte-
macrophage progenitor; GP, granulocyte progenitor; HSC, hematopoietic stem cell; 
MacP, macrophage progenitor; MEP, megakaryocyte-erythrocyte progenitor; MkP, 
megakaryocyte progenitor; NK, natural killer; Lin, lineage markers. [60] 
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sequential sites of hematopoiesis include the yolk sac, the aorta-gonad 
mesonephros (AGM) region (an area surrounding the dorsal aorta), the 
fetal liver, and the bone marrow. HSCs arise and migrate between these 
multiple sites until the bone marrow develops sufficiently to provide the 
environmental niches necessary for HSC function. The properties of HSCs 
in each site differ, presumably reflecting diverse niches that support HSC 
expansion and/or differentiation and intrinsic characteristics of HSCs at 
each stage. The fetal liver and the bone marrow are major organs for HSC 
expansion, maintenance and differentiation. Currently, two types of HSC 
niches have been identified in bone marrow: the endosteal niche located on 
the surface of trabecular bone, and the vascular niche at the bone marrow 
sinusoids, which are low-pressure blood vessels with a fenestrated 
endothelium located in the center of the bone marrow [61]. Osteoblasts are 
mesenchymal cells that produce the bone matrix to form the bone after 
mineralization, are found on the endosteal surface lining between the bone 
and the marrow, and secrete many cytokines that promote the proliferation 
of hematopoietic cells in culture, and support the in vitro maintenance of 
HSCs [62]. Osteoblasts probably regulate HSCs through cell-surface 
adhesion molecules and/or secreted signalling molecules, such as N-
cadherin and β1-integrin, important in anchoring HSC to the endosteal 
niche [63]. Osteoblasts also produce surface signalling ligands, such as 
Angiopoietin-1, which interact with HSC receptor Tie2. Thus osteoblasts 
probably regulate HSCs through cell-surface adhesion molecules and/or 
secreted signalling molecules. Endothelial cells and reticular cells were 
proposed to act as the niche cells that interact with HSCs within the 
sinusoidal vascular niche. They express high levels of the chemokine 
CXCL12 (also known as stromal-derived factor 1, SDF-1) that regulates the 
migration of HSCs to the vascular niche [64]. Different observations stated 
that long-term retaining HSCs are highly enriched at the bone surface 
compared to the center of marrow, raising the hypothesis that in endosteal 
niche HSCs are probably more quiescent than the HSCs residing in the 
vascular niche [65]. These characteristics suggest that HSCs reside in 
various sites within the marrow and that their function might depend on 
their precise localization. 
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1.4.2.1.%Phenotypic%characterization%of%HSCs%
The major obstacle to studying HSC biology is that the cells are extremely 
rare. Only 1 in 106 cells in human bone marrow are HSC [66], requiring 
purification from the bulk of differentiated cells. Purification of human HSCs 
requires simultaneous detection of several independent cell surface 
markers, so human HSCs and progenitors isolation have been 
characterized by enriching a rare cell population with a combination of 
monoclonal antibodies [67]. Over past years, various cell surface and 
metabolic markers have been identified and used to isolate human HSCs 
and progenitors. CD34 was the first identified marker found to enrich 
human HSCs as well as more differentiated progenitors, raising the need to 
search for additional markers for classification. To this end, further studies 
introduced CD90 (Thy1) as a stem cell marker and CD45RA and CD38 as 
markers of more differentiated progenitors that negatively enrich for HSCs, 
thus depicting human HSCs as CD34+CD38–Thy1+CD45RA- [68, 69]. Since 
other studies discovered subpopulation of HSCs that do not express 
detectable levels of CD34, another important marker of HSCs became 
CD133 (also known as PROM1), which is expressed on both CD34+CD38- 
cells and primitive CD34-CD38- subpopulations, therefore providing a more 
appropriate method to enrich stem cells than CD34 selection alone [70]. 
1.4.2.2.%Molecular%regulation%of%HSC%formation%and%self%renewal%
One of the major objectives of stem cell biology is to understand the 
cellular and molecular processes underlying HSCs fate choice. As intrinsic 
determinants of cellular phenotype, transcription factors provide an entry 
point for unravelling how HSCs develop during embryogenesis and how 
lineage-restricted differentiation is programmed. They can act both 
positively and negatively to regulate the expression of a wide range of 
genes including growth factors and their receptors, other transcription 
factors, as well as various molecules important for the function of 
developing cells. It is the alternative expression of specific combinations of 
transcription factors that determines the survival, proliferation, commitment, 
and differentiation responses of hematopoietic progenitors to signals that 
arise from extrinsic or intrinsic regulatory factors. For discussion purposes it 
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is possible to divide between factors required for HSC formation or function 
and those employed in lineage-specific differentiation [71]. Among the 
transcription factors involved in HSC formation are MLL (for mixed lineage-
leukemia gene), Runx1, TEL/ ETV6, SCL/tal1, and LMO2, all genes that 
are subject to translocations in leukemia patients. These factors have 
served roles later within differentiation of individual blood lineages, while 
factors that appear to have more lineage-restricted roles, such as PU.1, 
Gfi-1, and C/EBPa, act within HSCs. The basic-helix loop-helix (bHLH) 
factor SCL/tal-1 and its associated protein partner, LMO2, are individually 
essential for development of both the primitive and adult hematopoietic 
systems [72]. The genes encoding the SET-domain containing histone 
methyltransferase MLL and Runx1 proteins are essential for generation of 
HSCs within the AGM (and possibly at other sites) [73]. In the absence of 
Runx1, no hematopoietic clusters (representing presumptive HSCs) form in 
the dorsal aorta in mice. GATA2 is an indispensable transcription factor for 
hematopoiesis [74]. In mice, GATA2 is expressed in primitive 
hematopoietic cells and its level gradually declines during cell maturation 
into different blood cell lineages. GATA2-deficient embryos are anemic, 
have reduced numbers of hematopoietic progenitors and die prematurely. 
This transcription factor has at least two fundamental functions: the 
production and expansion of HSC in AGM, and the proliferation and 
survival of HSCs in adult bone marrow. The balance that controls between 
self-renewal and cell fate decision of HSCs in the bone marrow is mediated 
by several factors. Most HSCs are in quiescent state (i.e., in G0/G1 phase 
of the cell cycle), however, when the hematopoietic cells disturbance 
occurs, hematopoiesis system will respond by regulating several signal 
transduction pathways, such as SDF-1 (CXCL12)/CXCR4 signaling, BMP 
signaling, Mpl/Thrombopoietin (TPO) signaling, Tie2/Ang-1 signaling, 
hedgehog and Notch signaling, as well as Wnt signaling [75], to promote 
HSC self-renewal. Moreover, several transcription factors seem to be 
involved in the same process. For instance factors of the HOX and Ikaros 
families appear to be strong positive regulators of HSC self-renewal [76, 
77]. 
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1.4.2.3.%Molecular%regulation%of%lineage%commitment%
Once HSCs divide and generate more differentiated daughter cells, within 
10-15 divisions the genetic programs of the descendent cells become fixed 
toward a single lineage. The first step is represented by the restriction to 
the ability to generate myeloid versus lymphoid progeny respectively by 
CLPs, which express specifically GATA-3 and IKZF3 transcription factors, 
and CMPs, which are specifically regulated by the transcription factors 
SCL, GATA-2, NF-E2, GATA-1, C/EBPa, c-Myb, and PU.1 [78]. The 
alternative differentiation potential of these progenitors is not immediately 
eliminated, but rather repressed in a graded or gradual way in the cells that 
are committing to a given lineage. Whereas PU.1 and GATA-1 are co-
expressed in CMPs, their mutually exclusive expression coincides with 
further commitment to either granulocytic-monocytic or megakaryocytic-
erythroid differentiation. PU.1 was found to inhibit the transcriptional activity 
of GATA-1 upon its target genes, and vice versa. These effect are 
mediated by direct physical contact of PU.1 N-terminal part to the GATA-1 
C-terminal zinc finger that involves DNA binding, and, in a reverse way, 
through the interaction of the c-finger of GATA-1 with ETS domain of PU.1, 
precluding the recruitment of co-activator c-Jun in the context of the 
promoters of its target genes [79]. Models in which such transcription 
factors act as part of multimeric complexes best explain the context-
dependent action and direct antagonism between key transcriptional 
regulators. Indeed protein complex in erythroid cells comprised of GATA1 
(or its close relative, GATA-2), LMO2 and its partner Ldb1, and SCL/tal1 
and its heterodimeric partner E2A, recognizes a consensus GATA-E-box 
DNA motif. This complex is required for full erythroid and megakaryocytic 
cell maturation [72]. GATA factors form alternative protein complexes with 
a specific cofactor known as FOG (for friend of GATA) that is also essential 
for erythroid and megakaryocytic development. The GATA1 (or GATA-
2)/FOG1 complex in both erythroid and megakaryocytic lineages is 
physically associated with the NuRD chromatin remodelling complex via a 
NuRD binding motif at the N terminus of FOG1 [80]. In the context of the 
development of myeloid cells the dosage of PU.1 is important in defining 
cellular fates in the myeloid lineage. Approximately, low doses of PU.1 
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promote the development of granulocytes, while higher ones favor the 
development of monocytes. CCAAT enhancer-binding protein-α (C/EBP-α), 
a basic region leucine zipper transcription factor, is important for the 
production of granulocyte-macrophage progenitors from common myeloid 
progenitors. IFN-γ–responsive factor (IRF)–8 promotes differentiation into 
monocytes but not granulocytes, whereas GFI-1 is a transcription factor 
required for granulocyte development. In addition to transcriptional 
regulators, cell surface cytokine/growth factor receptors and proteins play a 
role in regulating erythroid and myeloid development [81].  
CD34+ cells are a heterogeneous population covering not only stem cells 
but also earlier multipotent progenitors and later lineage-restricted 
progenitors. In human hematopoiesis, populations enriched for HSC activity 
have been identified, but multipotent progenitor activity has not been 
uniquely isolated.  There is reason to believe that cells defined as human 
HSCs by the cell surface markers previously described are likely to include 
one or more multipotent progenitor populations. A previous study 
demonstrated that the CD34+ Lin- CD38- fraction of cord blood and bone 
marrow can be subdivided into three subpopulations: CD90+ CD45RA-, 
CD90- CD45RA-, and CD90-CD45RA+. The CD90+ CD45RA- subpopulation 
contains HSCs, while the CD90- CD45RA- subpopulation contains 
candidate multipotent progenitors [82]. This represented the first 
identification and prospective isolation of a population of candidate human 
MPPs. Recently it has been reported that CD49f antigen is expressed on 
about 50% of human CD90+ and about 25% of CD90- cells. When sorted 
fractions were assayed in vivo, HSC activity was restricted to the CD49f+ 
cells in both fractions. By contrast, CD90- CD49f– cells mediate transient 
multilineage repopulation that peaks at 4 weeks and becomes undetectable 
after 16 weeks [83]. In light of these studies, several markers, such as 
CD90, CD45RA and CD49f, can be used to distinguish MPPs from HSCs. 
The erythropoiesis starts with committed erythroid progenitors, the BFU-E 
(burst forming unit-erythroid), which expresses the cell surface antigen, 
CD34, as do all other early hematopoietic progenitors, but is CD36 positive. 
The next stage, the colony forming unit-erythroid (CFU-E), express also 
high level of CD71 antigen (the transferrin receptor), which then decreases 
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slightly during further maturation in pro-erythroblast, characterized by the 
presence of a euchromatic nucleus and visible nucleoli and the expression 
of glycophorin A on cell surface. This process is mainly due to the effect of 
EKLF transcription factor.  
On the myeloid side, GMPs differentiate from the CMPs. GMPs are CD34+ 
cells that are committed to differentiate into myeloid cells and can be 
commonly recognized by the surface expression of CD13 and CD33 
antigens on cell surface. Then these cells give rise to colony forming unit-
granulocyte (CFU-G) and colony forming unit- monocyte (CFU-M), mainly 
through the coordinated action of PU.1 and Gfi-1 transcription factors. 
1.4.2.4.%Chromatin%landscapes%in%HSC%differentiation%
In recent years different pathways and genes involved in hematopoiesis 
have been identified, but it remains unclear how the decision between self-
renewal and differentiation is controlled and how differentiation is specified 
at molecular levels. Recently the epigenetic profile of HSCs has been 
described, and some hypotheses about differentiation mechanisms were 
outlined [84]. In particular it has been shown that differentiation of CD133+ 
cells into CD36+ cells is accompanied by dramatic changes of histone 
modifications at critical genetic regions. For instance H3K4me3 and 
H3K27me3 counteracting modifications provide a mechanism of either 
gene activation or repression through a shift in their balance. These 
bivalent modifications maintain the activation or silencing potential of critical 
differentiation genes, in fact some of these “bivalent genes” can lose 
H3K4me3 while others can lose H3K27me3 during differentiation. In 
particular 20% of bivalent genes lose H3K27me3 becoming activated in 
transition to CD36, are associated to H3K4me1 and RNA PolII in HSCs, 
thus are likely to be poised for activation. These characteristics are 
consistent with a model in which the fate of bivalent genes (i.e. the 
induction of genes involved in one particular lineage and the silencing of 
genes required for other lineages) during differentiation is controlled by 
epigenetic modifications that occur in HSC commitment to hematopoietic 
progenitor cells (HPCs). Another chromatin-related striking characteristics 
of HSC commitment is the enhancer “priming” by specific histone 
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modifications, such as H3K4me1, H3K27me1, and H3K9me1 that are 
associated with critical regulatory elements in the cell stage before their 
target genes are expressed. In fact these marks are found to be present in 
LCR upstream human β-globin locus even if the globin genes are not 
expressed. Specific signatures at enhancers are also removed after 
differentiation, as in the case of neutrophil-specific myeloperoxidase gene 
(Mpo) that is primed for expression in HSCs through H3K4me1 and 
H3K9me1 marks in a region upstream the TSS, but does not show the 
same signature in CD36+ cells, causing a loss of activation potential after 
differentiation. Although the model of gradual transition from an open 
chromatin state in multipotent stem cells to a compacted state in more 
differential cell, progressively closing the regulatory potential of the 
genome, is widely accepted, it cannot explain some characteristics of the 
regulatory regions during HSCs differentiation. Recently, in fact, it has been 
proposed that enhancers can be de-novo specified during establishment of 
lineage progenitors through the action of pioneer factors that recognize 
specific sites in the genome, deposing H3K4me1 and eventually modify the 
chromatin landscape [85]. Together with H3K4me1 deposition, active 
enhancers are also marked by H3K27ac, but while the monomethylation 
usually appear first in the root lineage progenitors, the acetylation of H3K27 
is acquired later, together with activation of regulated genes. 
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1.5.'Aim'of'the'work'
The goals of this work are: 
 
1. Characterization of the transcriptional and epigenetic profiles of 
HSPCs and their early committed erythroid and myeloid progeny; 
 
2. Identification of active regulatory elements, responsible of the early 
commitment of HSPCs to erythroid and myeloid lineage-restricted 
progenitors; 
 
3. Development of a bioinformatic pipeline to analyse and integrate 
quantitative genomics data from epigenetic and transcriptomic 
experiments involving the application of NGS technologies in 
order to reach these goals. 
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2.'MATERIALS'AND'METHODS'
2.1.'Cell'types'
Thanks to the collaboration with San Raffalele Hospital (Milan, Italy), we 
obtained human umbilical cord blood from informed healthy donors in 
accordance with the Declaration of Helsinki. San Raffaele Scientific 
Institute Ethical Committee approved the study. Mononuclear cell were 
isolated using gradient separation (by Ficoll-Hypaque, Lymphoprep; 
Sentinel Diagnostics) and CD34+ cells were purified by immunomagnetic 
sorting (EasySep Human CD34 Positive Selection kit, StemCell 
Technologies Inc.). 
2.1.1.'Hematopoietic'stem/progenitor'cells'(HSPCs)'
We seeded CD34+ cells at 0.5-1x106 cells/ml and cultured them for 36h in 
IMDM medium (Lonza) containing 20% fetal bovine serum (FBS) (Hyclone) 
and supplemented with 100 ng/ml human stem cell factor (hSCF), 100 
ng/ml human Flt3-ligand (hFlt3-l), 20 ng/ml human trombopoietin (hTPO) 
and 20 ng/ml human Interleukin-6 (hIL-6) (all PeproTech). After 36h, we 
labeled the cells with fluorescein isothiocyanate (FITC)-conjugated anti-
CD34, phycoerythrin (PE)-conjugated anti-CD133 and tri-color (TC) anti-
CD38 antibodies. We sorted CD34+/CD133+ multipotent progenitors using 
a MoFlo cell sorter (Beckman Coulter). 
2.1.2.'Erythroid'progenitors'(EPPs)'
We cultured CD34+ cells for 5 days as described by Roselli et al. [86]. We 
seeded the cells at 105 cells/ml in StemSpan medium (Stem Cell 
Technologies) containing 20% FBS (Hyclone) and supplemented with 50 
ng/ml hSCF (Peprotech), 1 U/ml human erythropoietin (EPO) (Janssen), 1 
ng/ml hIL-3 (Peprotech), 10-6 M dexamethasone (Sigma), and 10-6 M ß-
estradiol (Sigma). At day 5, we labeled the cells with FITC-conjugated anti-
CD36 antibody and sorted CD36+ erythroid progenitors using a MoFlo cell 
sorter (Beckman Coulter). We also stained CD36+ cells with PE-conjugated 
anti-CD34, Allophycocyanin (APC)-conjugated anti-glycophorin A and 
Peridinin chlorophyll- conjugated (PerCP) anti-CD71 antibodies.  
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2.1.3.'Myeloid'progenitors'(MPPs)'
We cultured CD34+ cells at 105 cells/ml in IMDM medium (Lonza) 
containing 10% FBS (Hyclone) and supplemented with 100 ng/ml hSCF 
(Peprotech), 20 ng/ml hIL-3 (Peprotech), 100 ng/ml G-CSF 
(ITALFARMACO SpA). At day 5, we stained the cells with FITC-conjugated 
anti-CD34 and PE-conjugated anti-CD13 antibodies and purified 
CD13+/CD34- MPP using a MoFlo cell sorter (Beckman Coulter). We also 
labelled MPP with APC-conjugated anti-CD33 or APC-conjugated anti-
CD11b antibodies. 
 
We performed analyses by fluorescence-activated cell-sorter (FACS) using 
FACSCanto flow cytometer (BD Biosciences). Appendix table 6.1 reports 
the complete list of antibodies used for FACS. 
2.1.4.'CFU'assay'
We plated multipotent and lineage–committed progenitors cells at 103 
cells/ml in methylcellulose medium (GFH4434, Stem Cell Technologies). 
We scored burst forming unit-erythroid (BFU-E), unit-granulocyte/ 
macrophage (CFU-GM) and unit-granulocyte/erythroid/macrophage/ 
megakaryocyte (CFU-GEMM) colonies after 14 days. 
2.1.5.'Gene'expression'profiling'
We determined the transcriptional profiles of multipotent and lineage–
committed progenitors using Affymetrix HG-U133 Plus 2.0 GeneChip 
arrays (3 samples for each population) (Affymetrix, Santa Clara, CA). We 
preprocessed and normalized the data in R (“Affy” package). We annotated 
the arrays using a custom chip definition file, the Gene Annot CDF for 
Human Gene U133 Plus 2.0 arrays, and the corresponding Bioconductor 
libraries [87]. We used DNA-Chip Analyzer (dChip) (www.dchip.org) 
software [88] to identify differentially expressed genes and perform 
hierarchical clustering.  
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2.2.'ChIP@seq'
2.2.1.'ChIP'assay'
We prepared chromatin from EPP and MPP after cross-linking for 10’ at RT 
with 1% formaldehyde- containing medium, using truChIPTM High Cell 
Chromatin Shearing Kit with SDS Shearing Buffer (Covaris). We sonicated 
nuclear extracts to obtain DNA fragments averaging 200 bp in length and 
immunoprecipitated the equivalent of 107 cells overnight with 10 µg of 
rabbit antibodies against H3K4me1 (ab8895, Abcam), H3K4me3 (ab8580, 
Abcam), and H3K27ac (ab4729, Abcam), as previously described [84, 89]. 
We used real-time SYBR Green PCR to validate genomic regions enriched 
in H3K4me1, H3K4me3 and H3K27ac. 
2.2.2.'ChIP@seq'library'preparation'and'sequencing''
We prepared Illumina libraries, for EPP and MPP, starting from 10 ng of 
immunoprecipitated DNA (IP) and control DNA (INPUT: nuclear extracts 
sonicated but non-immunoprecipitated) following the Illumina ChIP-seq 
DNA sample preparation kit. We checked the libraries by capillary 
electrophoresis by Agilent Bioanalyzer 2100 with the High sensitivity DNA 
assay and quantified them with Quant-iTTM PicoGreen® dsDNA Kits 
(Invitrogen) by Nanodrop Fluorometer. We sequenced each library in one 
lane of a single strand 51 bp Illumina GAIIx run. 
2.2.3.'Bioinformatic'data'analysis'
We mapped raw reads against the human reference genome (build hg19) 
using Bowtie [10] allowing up to 2 or 3 mismatches. We then processed 
each BAM file by using SAMtools [90], and converted each into a bed file 
using BEDTools [91]. We checked the quality of each sequenced sample 
using cross-correlation analysis implemented in spp R package (version 
1.11) [12], shifting strands by a window of -50/+500 bp. All the quality 
control steps were performed using custom scripts in R programming 
language (http://cran.r-project.org/). For each sample the normalised strand 
coefficient (NSC) and the relative strand correlation (RSC) were calculated 
dividing the highest values in cross-correlation by the minimum value in 
cross-correlation in strand shift windows and by the cross-correlation value 
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relative to read-length strand shift [92]. Saturation analysis was performed 
downsampling each sample in 10 steps. At each step 5% of the total 
amount of reads was randomly removed, broad regions were called using 
spp R package [12] and compared to the regions called using the total set. 
Plots of histone modification signal at genomic features were performed 
using ngs.plot functions [93]. We performed ChIP-seq peak calling using 
SICER default parameters [14] and using each INPUT data to model the 
background noise. We downloaded HSPC raw H3K4me3, H3K4me1 and 
H3K27ac ChIP-seq data from the NIH Roadmap Epigenomics Mapping 
Consortium database (http://www.roadmapepigenomics.org/; GSM773041, 
GSM773043, GSM772894) and analysed them as described above for 
EPP and MPP. 
2.2.4.'Identification'of'cis@regulatory'elements''
We developed a custom R-workflow to identify promoters and enhancers. 
The pipeline analyses the histone modification islands generated by SICER 
and includes three steps. In the first step, the R script invokes BEDtools 
[91] to identify regions where H3K4me1 overlaps or does not overlap with 
H3K4me3. H3K4me3+/H3K4me1- and H3K4me3-/H3K4me1+ regions are 
classified as putative promoters and enhancers, respectively. In the second 
step, the R script first normalizes the tag counts of H3K4me3 and 
H3K4me1 using the sequencing depths of both libraries and then 
calculates the log-ratios between H3K4me3 and H3K4me1 tag counts for 
H3K4me3+/H3K4me1+ regions. If the H3K4me3/H3K4me1 ratio is greater 
than 0, the region is defined as putative promoter, otherwise as putative 
enhancer. Regions identified with this method were then merged with 
H3K4me3+/H3K4me1- and H3K4me3-/H3K4me1+ to have the complete sets 
of putative promoters and putative enhancers, respectively. Finally, we 
intersected putative regulatory elements with H3K27ac+ regions to identify 
active chromatin regions.  
'
'
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2.3.'CAGE'
2.3.1.'Library'preparation,'sequencing'and'mapping''
We extracted RNA from multipotent and lineage-committed progenitors 
using RNeasy Plus Mini kit (QIAGEN). DNAFORM Inc. at RIKEN Omics 
Science Center (Yokohama, Japan) performed DeepCAGE library 
preparation. Briefly, the cDNA synthesis was performed with 5 µg of total 
RNA, the random (N15) reverse-transcription primers and PrimeScript 
Reverse Transcriptase (TAKARA). Capped RNA was biotinylated and 
treated with RnaseOne. Then, hybrid cDNA with biotinylated Capped RNA 
was selected with cap-trapper method [94]. cDNA was released from 
streptavidin beads. A sample-specific linker, containing a recognition site 
for the sample-specific barcode sequence (3 bp) and the type III restriction-
modification enzyme EcoP15I, was ligated to the single-strand cDNA. After 
ligation, the 2nd strand synthesis was performed and the resulting double-
stranded cDNA was cleaved with EcoP15I. After, a second linker was 
ligated to the CAGE tag. The CAGE tags were separated from unmodified 
DNA with streptavidin beads. Then, the DNA fragments were PCR-
amplified by using linker-specific primers. Each library was sequenced in 
one lane of a single strand 38 bp Illumina GAIIx run. 13 to 15 million reads 
were obtained per lane. DNAFORM at RIKEN GeNAS performed CAGE 
data analysis. Briefly, tags were extracted and mapped to human genome 
version hg19 (NCBI build 37), with a minimum match length of 21 bases 
and a maximum of one error; tags mapping the human ribosomal DNA 
sequence were eliminated. For CAGE tags mapping to multiple genome 
locations, a weighting strategy, based on the number of CAGE tags within 
a 200bp neighbourhood around each candidate mapping location, was 
applied. Equal weights were used if no unique tags were found within the 
200 bp region for all candidate mapping locations [95]. The average 
mapping rate was 40%.  
2.3.2.'Promoter'construction'
We defined level-1 promoters ("transcription start sites") by summing the 
weighted number of CAGE tags at each genome position. Then we 
clustered level-1 promoters into level-2 promoters ("promoters") if they 
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were within 20 bp of each other on the same chromosomal strand. We 
calculated the expression level for each level-1 and level-2 promoter by 
dividing the number of CAGE tags of each promoter in each experimental 
condition by the total number of mapped CAGE tags in that condition, and 
multiplying by 106 (tags-per-million, TPM). The expression of each level-2 
promoter of at least 10 TPM in at least one experimental condition was 
imposed.  
2.3.3.'Promoter'annotation'
We annotated transcription start sites using gene tracks from UCSC 
Genome Browser (https://genome.ucsc.edu). We annotated CAGE 
promoters on the base of their proximity to RefSeq genes, ENSEMBL 
ncRNA, ncRNA included in publicly available data sets [29, 96, 97], 
Vertebrate Genome Annotation (Vega) pseudogenes [98] and Yale 
Gerstein Group pseudogenes [99]. For each dataset, we found the 
annotation with the smallest distance to the CAGE-defined promoter on the 
same chromosome strand. We defined the distance as follows: 1. If the 3' 
end of the promoter was upstream of the 5' end of the annotation, then we 
used the distance between the 3' end of the promoter and the 5' end of the 
annotation. 2. If the 5' end of the promoter was downstream of the 5' end of 
the annotation, then we used the distance between the 5' of the annotation 
and the 5' end of the promoter. 3. Otherwise, the promoter overlapped the 
5' end of the annotation. In this case, we considered the distance to be 
zero. If this distance was less than 400 bp, we associated this promoter to 
the gene or transcript.  
2.3.4.'Statistical'analysis'
We performed statistical differential analysis on level-2 promoters using 
edgeR [100] and raw count data (i.e. the number of cage tags within each 
promoter), manually setting dispersion value to 0.09. 
! 37!
3.'RESULTS'AND'DISCUSSION'
3.1.'Purification'and'characterization'of'multipotent'and'
lineage@restricted'hematopoietic'progenitors'
Hematopoietic stem/progenitor cells (HSPCs) were obtained from cord 
blood of fully informed donors. HSPCs were enriched as CD34+ CD133+ 
populations by FACS sorting and pooled from different donors. Committed 
erythroid and myeloid progenitors were FACS-enriched as pools of 
CD34low/CD36high and CD34-/CD13+ populations, respectively, after 
induction to differentiation in the appropriate conditions [86]. In order to 
characterize HSPCs and their erythroid and myeloid progeny, we 
investigated the presence of several surface markers by staining the cells 
with specific antibodies and performing flow cytometric analysis. HSPCs 
showed high levels of CD38, indicating that the majority of the cells was 
early hematopoietic progenitors [101]. The 95% of erythroid 
CD34low/CD36high cells were CD71-positive and expressed low or 
undetectable levels of glycophorin A (GYPA), indicating that they are mainly 
composed by CFU-E and BFU-E progenitors [102], while MPP expressed 
the myeloid differentiation markers CD33 (99%) and CD11b (95%) [103] 
(Figure 4). 
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To better characterize the composition of the cell populations, we 
performed a colony forming cell (CFC) assay, which assessed in vitro 
primitive human hematopoietic progenitors. A defined number of 
hematopoietic cells was seeded within a semi-solid (methylcellulose) 
medium that supports the growth of human progenitors and the 
development of erythroid and myeloid lineages, and resulted in the 
formation of discrete colonies of various morphologies. The colonies were 
classified into six different types: colony forming unit-erythroid (CFU-E), 
burst forming unit-erythroid (BFU-E), colony forming unit-
granulocyte/macrophage (CFU-GM), colony forming unit-granulocyte (CFU-
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Figure 4. Purification and characterization of multipotent and lineage-restricted 
hematopoietic progenitors. (A-C) FACS analysis and CFC assay of HSPC, EPP and 
MPP. 
! 39!
G), colony forming unit-macrophage (CFU-M), colony forming unit-
granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM).  
After 14 days, HSPCs gave rise to mixed cell colonies (CFU-GEMM), and 
both myeloid (CFU-GM, CFU-G, CFU-M) and erythroid (BFU-E and CFU-
E) colonies, thus confirming their multilineage potential. In contrast, EPP 
and MPP populations generated >90% erythroid (BFU-E and CFU-E) and 
myeloid (CFU-GM, CFU-G, CFU-M) colonies respectively, confirming their 
lineage-restricted potential (Figure 5). 
 
 
Figure 5. CFC assay. CFU-E, colony forming unit-erythroid; BFUE, burst forming 
unit-erythroid; CFU-M, colony forming unit-macrophage; CFU-G, colony forming 
unit-granulocyte; CFU-GM, colony forming unit-granulocyte/macrophage; CFU-
GEMM, colony forming unit-granulocyte/erythroid/macrophage/megakaryocyte. 
 
Global microarray gene expression profiling was used in order to identify 
genes enriched in each individual population and firmly establish their 
distinct identity. Microarray analysis was performed using mRNA isolated 
from CD34+/CD133+ HSPCs, erythroid CD34low/CD36high and myeloid 
CD34-/CD13+ cells using Affymetrix Human Genome U133 Plus 2.0 array. 
Supervised analysis was performed using a fold‐change equal to of greater 
than 2 and a p-value threshold of 0.05, to obtain differentially-expressed 
genes (DEGs). This analysis identified 415 DEGs between CD34+/CD133+ 
HSPCs and erythroid CD34low/CD36high cells, of which 177 down-regulated 
and 238 up-regulated as a result of erythroid cells differentiation, and 126 
DEGs between CD34+/CD133+ HSPCs and myeloid CD34-/CD13+ cells, of 
which 41 down-regulated and 85 up-regulated upon myeloid differentiation. 
Genes down-regulated in both conditions belong to TGFβ/BMP signaling 
pathways implicated in HSC self-renewal (e.g. NOG, CHRDL1, TGFB1I1), 
or to the tumour necrosis factor superfamily, involved in T- and B-cell 
CFU-E 
BFUE 
CFU-M 
CFU-G 
CFU-GM 
CFU-GEMM 
CFU-E 
BFUE 
CFU-M 
CFU-G 
CFU-GM 
CFU-GEMM 
CFU-E 
BFUE 
CFU-M 
CFU-G 
CFU-GM 
CFU-GEMM 
HSPC EPP MPP 
! 40!
functions (e.g. TNFSF13B, TNFSF4, LTB), while genes involved in 
leukocyte activation and immune response (e.g. MPO, CTSG, GZMA) were 
down-regulated specifically upon erythroid commitment. Genes up-
regulated in EPP are mainly involved in erythrocyte differentiation, 
maturation and homeostasis (e.g., HBB, AHSP, ANK1, PKLR, CD36, 
GYPA, DNTM), and include the master transcriptional regulators GATA1 
and KLF1. Instead, genes up-regulated in MPP are mainly involved in 
inflammatory response and immune defence function of neutrophils and 
macrophages (e.g., ELANE, AZU1, CTSG). For the complete list of DEGs, 
refer to appendix.  
Taken together, these results confirmed the identity of the hematopoietic 
populations analysed in this study. CD34+/CD133+ cells well represent an 
enriched population of multilineage stem/progenitor hematopoietic cells, 
CD34low/CD36high cells are representative of committed erythroid 
progenitors, while CD34-/CD13+ cells have a distinct myeloid phenotype. 
! '
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3.2.'Characterization'of'regulatory'elements'usage'in'HSPC'and'
lineage@restricted'progenitors'
In order to obtain a genome-wide description of chromatin changes 
occurring upon HSPC commitment, we performed ChIP sequencing 
experiments in EPPs and MPPs, and used publicly available data sets for 
HSPCs. We designed ChIP-seq analyses on histone methylations typical of 
promoters and enhancers, H3K4me3 and H3K4me1 respectively, and on 
histone acetylation H3K27ac known to mark active regulatory elements. 
We then employed a bioinformatic framework for data analysis and 
integration in order to define and characterize regulatory elements in HSPC 
and lineage-restricted progenitors EPP and MPP. 
3.2.1.'Genome@wide'histone'modification'profiling'by'ChIP'sequencing'
3.2.1.1.%Quality%assessment%of%ChIPFseq%data%
We designed ChIP-seq experiments on H3K4me1, H3K4me3 and 
H3K27ac in order to define regulatory elements in EPPs and MPPs, and 
reprocessed public datasets for HSPCs (GSE17312). For each cell type an 
Input sample was generated, in order to control for background. Chromatin 
was prepared and sonicated in order to obtain DNA fragments averaging 
200 bp in length; each library was sequenced using Illumina platform, 
generating a total of more than 370 million reads of 51 bp in length. These 
reads represent the 5’ of library fragments from either DNA strand. The 
positions of the raw reads were then determined mapping them against 
human reference genome (build hg19), allowing up to two mismatches in 
order to maximize the number of aligned reads and discarding ambiguous 
alignments (i.e. reads mapped to multiple genomic position). In this step 
the alignment parameters are kept stringent in order to avoid the mapping 
of spurious tags that can increase the noise of a ChIP-seq experiment. In 
fact a previous study [12] showed that reads at least 25 bp long 
significantly increase the cross-correlation profiles (expression of signal-to-
noise ratio) of IP data when mapped with two mismatches. Using these 
criteria, we mapped a total of 344,985,809 reads, samples ranging from 
about 12 millions to 31 million reads (Table 1). 
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sample mapped reads NRF FRiP NSC RSC 
HSPC_H3K4me3* 31,131,313 0.78 0.82 2.08 1.07 
HSPC_H3K4me1* 31,276,729 0.85 0.74 1.25 1.10 
HSCP_H3K27ac* 31,602,356 0.40 0.40 1.46 1.49 
HSCP_input* 39,436,811 0.97 - 1.01 0.64 
EPP_H3K4me3 28,128,391 0.75 0.85 1.30 1.02 
EPP_H3K4me1 26,185,846 0.94 0.32 1.27 1.19 
EPP_H3K27ac 25,763,530 0.72 0.07 1.15 2.03 
EPP_input 20,272,745 0.98 - 1.04 0.73 
MPP_H3K4me3 28,732,471 0.43 0.81 3.02 1.05 
MPP_H3K4me1 27,091,353 0.71 0.19 1.19 1.21 
MPP_H3K27ac 37,720,127 0.30 0.12 1.81 2.90 
MPP_input 23,370,210 0.54 - 1.04 1.38 
Table 1. Sequencing data and QC statistics. NRF: Non-Redundant Fraction of 
mapped reads; FRiP: Fraction of Reads inside Peaks; NSC: normalized strand 
coefficient; RSC: relative strand correlation; *data from GSE17312 were 
reprocessed as EPP and MPP samples. 
An automatic pipeline was set up for data quality control and to facilitate the 
reproducibility of the analyses. 
We first checked if the depth of sequencing was high enough to robustly 
call the enriched regions in all samples. In order to do so, we performed a 
saturation analysis [92], progressively downsampling each sample and 
finding broad enriched regions using spp [12]. We found that H3K4me3 and 
H3K4me1 samples reached the saturation point at 90% of mapped reads, 
while H3K27ac samples were close to saturation point (Figure 6). Moreover 
a recent study demonstrated that these levels of mapped reads were 
acceptable for most applications [104]. We concluded that the amount of 
mapped reads of each sample is sufficient for exhaustively calling the 
enriched regions of histone modifications under study. 
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In order to verify the good performance of our ChIP-seq experiments, we 
computed the fraction of non-redundant mapped reads for all the data sets 
and for IP samples we obtained values between 0.3 and 0.85, that are 
considered sufficiently high for histone modification ChIP-seq data, while, 
as expected, for input samples NRF values were close to 1, indicating that 
they are representative of the background signal along the whole genome 
(Table 1). The alignment step produced typical read distributions of a ChIP-
seq experiment, with significant clustering of enriched DNA sequences at 
locations bound by the protein of interest, with mapped reads accumulated 
on forward and reverse strands roughly centred around the binding site. 
Because of this binding characteristic, we inspected the quality of the IP 
samples using cross-correlation analysis. The two DNA strands were 
shifted relative to each other by increasing distances in 500 steps, 
measuring the correlation between the enrichment at positive and negative 
strand at each step. A typical cross-correlation profile shows a maximum in 
correlation correspondent to the strand shift value of the library fragment 
and a second one that is a local maximum in cross correlation when the 
strands are shifted for the read length (read-length peak). We obtained 
cross-correlation profiles resembling typical situations of good ChIP-seq 
experiments (Figure 7).  
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Figure 6. Check for sufficient sequencing depth. 
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Figure 7. Cross-correlation profiles. For each sample the cross-correlation at 
specific strand shift values is plotted. The magnitude of the peak reflects the fraction 
of tags in the data set that appears in accordance with the expected binding tag 
pattern. 
 
A deeper analysis of cross-correlation profiles has been set up by 
ENCODE consortium, which proposed two metrics to estimate the signal-
to-noise ratios in ChIP-seq experiments, measuring the ratio between 
fragment-length peak and the minimum value of cross correlation 
(normalized strand coefficient, NSC) and the ratio between the fragment-
length peak and the read-length peak (relative strand correlation, RSC). 
For all the IP samples, we obtained values of NSC and RSC scores above 
minimum thresholds of 1.05 and 0.8, respectively (Table 1). 
Good ChIP-seq experiments should show good enrichments relatively to 
annotated genomic elements, such as TSSs, TESs, and gene bodies. In 
order to verify enrichment at precise locations relative to genes, we plotted 
the normalized signals of assayed histone modification. For all the cell 
types we noted typical profiles of H3K4me3 enrichment at 5’ of Ensembl 
genes, with peaks surrounding the TSS and a decrease of the signal upon 
it due to the physical occupancy of the transcriptional machinery, while 
H3K4me1 and H3K27ac signals remained lower, accordingly with the 
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nature of these histone modifications that do not typically mark promoters 
(Figure 8). These results suggest that H3K4me3 and H3K4me1 could be 
used to epigenetically discriminate transcription initiation at promoters from 
distal regions of open chromatin, typically associated to CREs, such as 
enhancers.  
 
Figure 8. Histone mark enrichment at transcription start sites. 
 
Finally we measured the global ChIP-enrichment, calculating the fraction of 
reads in enriched regions (FRiP) for each experiment. Although this 
analysis is typically performed for transcription factor ChIP-seq 
experiments, it can also help to evaluate the performance of IP 
experiments involving histone modifications. As expected, all the samples 
showed FRiP values above the minimum threshold of 0.01 [92] (Table 1).  
In summary we performed a comprehensive evaluation of the quality of 
ChIP-seq experiments, considering depth of sequencing, library complexity, 
visual assessment of ChIP-seq profiles, global ChIP enrichment and cross-
correlation analysis. Overall these results reflect the good quality of ChIP-
seq data, thus representing a positive starting point for the downstream 
analyses.  
3.2.1.1.%Identification%of%histone%modifications%enriched%regions%
In order to identify the significantly enriched regions for each mark, we 
applied a peak calling procedure. Since H3K4me3, H3K4me1 and 
H3K27ac marks are broad, lack of well-defined peaks and span from 
several nucleosomes to very large domains, we decided to use SICER [14], 
a specific algorithm designed to deal with this kind of data. For each 
sample, we tuned the gap size (g), a SICER parameter that defines the 
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distance between two consecutive significant islands, to maximize their 
aggregate score. 
Using this approach, we identified numbers of enriched regions ranging 
from 27,172 to 48,799 for H3K4me3, from 56,808 to 96,569 H3K4me1 and 
between 28,259 and 31,094 for H3K27ac mark (Table 2). 
 
HMs cell Tot median (bp) Q1 (bp) Q3 (bp) G.C. (%) 
H3K4me3 
HSPC 48,799 1,600 1,000 2,600 3.2 
EPP 27,172 2,000 1,200 3,400 2.3 
MPP 30,346 1,600 1,000 2,600 2.0 
H3K4me1 
HSPC 96,569 1,600 1,000 2,800 7.8 
EPP 56,808 3,200 2,000 5,800 9.3 
MPP 86,741 2,400 1,600 4,000 9.7 
H3K27ac 
HSPC 31,030 3,800 2,400 6,000 5.2 
EPP 28,259 4,000 2,600 6,000 4.7 
MPP 31,094 2,800 1,800 4,000 3.4 
Table 2. Statistics of histone modifications enriched regions. Tot: number of 
enriched regions identified; median, Q1 and Q3: median, first and third quantile of 
enriched regions length distributions; G.C.: genome coverage. 
These results were consistent with the nature of the histone modifications 
involved in the study. H3K4me1 and H3K27ac showed larger enriched 
regions and higher genomic coverage, compared to H3K4me3, as 
expected from histone modification known to mark large intergenic regions 
instead of 5’ end of genes.  
3.2.2.'Identification'of'regulatory'elements'
The identification of cis-regulatory elements is of striking importance for the 
study of molecular mechanisms at the basis of stem cell self–renewal, 
commitment and differentiation. In order to define putative promoters and 
putative enhancers in HSPC, EPP and MPP cells, we developed a custom 
bioinformatics workflow using ChIP-seq signals of H3K4me1 and H3K4me3 
histone marks. Then we used H3K27ac histone mark to distinguish active 
(H3K27ac+) promoters and active enhancers. 
%
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3.2.2.1.%Definition%of%promoters%and%enhancers%by%ChIPFseq%data%
integration%
In recent years several bioinformatics tools have been designed to 
characterize genomic regulatory elements, using different approaches 
depending on the number and the type of histone modification involved. As 
general rule, high levels of H3K4me1 and low levels of H3K4me3 
characterize strong-enhancers, but other histone marks, like H3K27ac, can 
be informative to detect enhancers that are active in one defined tissue and 
at a particular differentiation step. In our case the experimental model is 
composed by H3K4me1, H3K4me3 and H3K27ac, thus the identification of 
promoters and enhancers can be realized using computational methods 
that integrate the information of the enrichment of the first two marks [23] 
with the presence of the latter one to discriminate a subset of cell-specific 
active enhancers that may drive the HSPC commitment. We developed a 
custom R pipeline that takes as inputs the enriched regions identified using 
SICER from our ChIP-seq data sets and classifies the regions in three 
categories: regions characterized by the co-localization of both methylation 
marks (H3K4me3+/H3K4me1+), and regions having only one of the two 
methylation mark peaks (H3K4me3+/H3K4me1- and H3K4me3-
/H3K4me1+). In order to assign H3K4me3+/H3K4me1+ regions to one cis-
regulatory element category, we proceeded with the following steps: i) 
identification of overlaps between H3K4me1 and H3K4me3 regions; ii) 
normalization of raw read counts by the sequencing depths for both marks; 
iii) calculation of log-ratio between the two signals; iv) labelling of promoters 
and enhancers if log-ratio is lower or greater than zero, respectively. 
Promoters classified in this way are then merged with 
H3K4me3+/H3K4me1- regions and enhancers with H3K4me3-/H3K4me1+ in 
order to have complete sets of putative promoters and putative enhancers. 
With these annotations, in total we identified more than 30,000 promoter 
regions in HSPC, EPP and MPP, with a similar average size, and we 
defined from 40,000 to 70,000 putative enhancers in both multipotent and 
committed progenitors with similar length distributions (Table 3). 
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cell Tot. promoters median (bp) Q1 (bp) Q3 (bp) 
HPSC 17,810 3,000 1,600 4,800 
EPP 12,045 5,000 2,800 8,400 
MPP 13,185 4,000 2,400 6,200 
cell Tot. enhancers median (bp) Q1 (bp) Q3 (bp) 
HPSC 77,064 3,800 2,400 6,000 
EPP 45,349 4,000 2,600 6,000 
MPP 74,264 2,800 1,800 4,000 
Table 3. Statistics of all promoters and enhancers identified by ChIP-seq data 
integration. Tot: number of regulatory elements identified; median, Q1 and Q3: 
median, first and third quantile of enriched regions length distributions. 
In order to define active regulatory elements, we integrated promoters and 
enhancers with enriched regions of H3K27ac, a marker of active regions. 
We applied a very stringent method, defining as “active promoters” and 
“active enhancers” those putative regulatory elements that were covered 
with H3K27ac signal for at least 50% of their length. We found that more 
than 50% of putative promoters and about 20% of putative enhancers 
carried H3K27ac marker in HSPC, while lower percentages of cis-
regulatory elements associated with activation were found for EPP and 
MPP, consistently with the hypothesis that large portions of HSPC genome 
are silenced during commitment (Table 4). 
 
cell Tot. promoters median (bp) Q1 (bp) Q3 (bp) 
HPSC 9,671 (54%*) 3,200 2,000 4,800 
EPP 4,996 (41%*) 3,400 2,200 5,200 
MPP 3,672 (27%*) 2,400 1,600 3,600 
cell Tot. enhancers median (bp) Q1 (bp) Q3 (bp) 
HPSC 15,338 (19%*) 2,400 1,400 4,200 
EPP 7,221 (15%*) 2,800 1,800 5,000 
MPP 3,336 (4%*) 1,800 1,200 2,800 
Table 4. Statistics of H3K27ac+ promoters and enhancers identified by ChIP-
seq data integration. Tot: number of active regulatory elements identified; median, 
Q1 and Q3: median, first and third quantile of enriched regions length distributions; 
*percentage of the total number of regulatory elements reported in Table 3. 
%
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3.2.2.2.%Comparative%analysis%of%active%cisFregulatory%elements%in%HSPC,%
EPP%and%MPP%
We evaluated the dynamics of promoters and enhancers upon HSPC 
commitment in order to identify changes in cis-regulatory elements usage 
that are responsible of early lineage-restricted progenitor definition. We 
found that the great majority of EPP and MPP (92% and 93%, respectively) 
active promoter regions are shared with HSPC. Conversely a much lower 
proportion of active enhancers are shared upon lineage commitment while 
the majority are cell-specific (Figure 9), suggesting that enhancers play a 
major role in HSPC commitment.  
 
Figure 9. Dynamics of promoter and enhancer chromatin signatures upon 
HSPC commitment. Venn diagrams show the overlap of strong (H3K27ac+) 
promoters (H3K4me3>H3K4me1) and enhancers (H3K4me1>H3K4me3) identified 
in HSPC, EPP and MPP. Values in intersections refers to HSPC, those in brackets 
to EPP and MPP. 
Figure 10 shows an example of active enhancers identified at LCR of β-
globin locus only in HSPC and EPP (Figure 10).  In HSPC enhancers are 
already active, prior to erythroid commitment. These regulatory elements 
are then switched off in myeloid commitment, as can be seen evaluating 
H3K4me1 and H3K27ac signals at LCR. 
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Figure 10. Example of identified enhancer regions at human beta globin locus. 
The shaded regions showed the enhancers identified in HSPC and EPP at locus 
control region. MPP do not show enrichments in active enhancer-specific histone 
marks.!
 
We next explored whether enhancer maps might reveal trans-regulatory 
factors involved in the HSPC commitment gene expression regulation. 
Motif analysis performed with HOMER [17] showed that ChIP-defined cell-
specific active enhancers are enriched in binding sites for general and 
hematopoietic TFs (Table 5). Among the most represented motifs spanning 
all the three cell types, there are members of ETS TF family, that are the 
core of the gene regulatory networks controlling the key aspects of 
hematopoietic specification during embryogenesis as well as the 
maintenance and differentiation of HSCs [105]. Along with these factors, 
members of AP-1 complex (e.g. Jun, Fos, Fra1) are also represented 
HSPC, EPP and MPP, consistent with their roles in functional development 
of hematopoietic precursor cells into mature blood cells along most of the 
hematopoietic cell lineages [106]. Similarly, BATF, Bach1 and Bach2 motifs 
are enriched in active enhancers of all three cell types. BATF1 has been 
shown to limit the self-renewal of HSCs thus promoting the commitment 
and differentiation [107], while Bach1 and Bach2 have been reported to 
suppress the myeloid lineage and promote the lymphoid lineage [108], 
suggesting that at the stages of HSPCs, EPP and MPP they may act with 
different mechanisms. Interestingly, HSPC active enhancers were 
exclusively enriched in RUNX1 and IRF2 motifs, which are TFs involved in 
regulating the development and maintenance of HSCs [109] and in 
10kb 
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protecting the quiescent HSCs from differentiation [110], respectively. 
Moreover EPP and MPP active enhancers were specifically enriched in 
GATA factors and PU.1 motifs, respectively, indicating that their regulatory 
activities of megakaryocytic-erythroid and granulocytic-monocytic cell fates 
are already present at this stage of commitment. MPP were also 
specifically enriched in the motif of SpiB TF, which is required in myeloid 
specification [111]. 
a) HSPC-active enhancers 
Motif Name P-value Target BG 
 
ETS1(ETS) 1e-242 71.61% 56.71% 
 
Fli1(ETS) 1e-233 70.85% 56.19% 
 
ETV1(ETS) 1e-219 80.63% 67.53% 
 
PU.1(ETS) 1e-210 47.11% 33.25% 
 
GABPA(ETS) 1e-205 63.11% 49.05% 
 
ERG(ETS) 1e-201 87.07% 75.85% 
 
ELF5(ETS) 1e-155 60.51% 48.24% 
 
EHF(ETS) 1e-139 81.27% 71.15% 
 
SpiB(ETS) 1e-111 27.37% 18.84% 
 
Elk1(ETS) 1e-94 35.00% 26.32% 
 
Elk4(ETS) 1e-93 34.46% 25.89% 
 
SPDEF(ETS) 1e-81 66.35% 57.71% 
 
ELF1(ETS) 1e-79 33.70% 25.83% 
 
RUNX1(Runt) 1e-59 69.43% 62.21% 
 
NF-E2(bZIP) 1e-46 6.57% 3.78% 
 
RUNX2(Runt) 1e-43 61.48% 55.13% 
 
Bach2(bZIP) 1e-43 16.95% 12.51% 
 
Bach1(bZIP) 1e-42 6.30% 3.68% 
 
Nrf2(bZIP) 1e-41 5.63% 3.19% 
 
Fosl2(bZIP) 1e-40 26.95% 21.73% 
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Jun-AP1(bZIP) 1e-39 20.36% 15.72% 
 
IRF1(IRF) 1e-38 17.67% 13.38% 
 
Gata2(Zf) 1e-36 53.72% 47.82% 
 
MyoD(bHLH) 1e-34 45.82% 40.22% 
 
BMYB(HTH) 1e-33 79.23% 74.42% 
 
Gata1(Zf) 1e-32 48.81% 43.30% 
 
AMYB(HTH) 1e-31 79.11% 74.44% 
 
Fra1(bZIP) 1e-31 43.71% 38.40% 
 
Atf3(bZIP) 1e-31 49.59% 44.21% 
 
IRF2(IRF) 1e-29 12.77% 9.53% 
 
MYB(HTH) 1e-29 83.08% 78.94% 
 
BATF(bZIP) 1e-27 48.68% 43.66% 
 
ISRE(IRF) 1e-26 8.62% 6.09% 
 
Bcl6(Zf) 1e-26 78.42% 74.13% 
b) EPP-active enhancers 
Motif Name P-value Target BG 
 
Gata1(Zf) 1e-84 59.59% 46.28% 
 
Gata2(Zf) 1e-78 64.05% 51.33% 
 
Gata4(Zf0 1e-60 79.89% 70.00% 
 
Fosl2(bZIP) 1e-46 29.35% 21.01% 
 
Jun(bZIP) 1e-45 22.71% 15.30% 
 
GATA:SCL 1e-45 15.26% 9.17% 
 
Bach1(bZIP) 1e-40 7.51% 3.62% 
 
GATA3(Zf) 1e-36 91.97% 86.42% 
 
NF-E2(bZIP) 1e-34 7.21% 3.65% 
 
GABPA(ETS) 1e-33 53.85% 45.52% 
 
Fra1(bZIP) 1e-30 47.10% 39.39% 
 
BATF(bZIP) 1e-29 52.66% 44.92% 
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Bach2(bZIP) 1e-28 17.23% 11.98% 
 
Nrf2(bZIP) 1e-27 6.08% 3.13% 
 
Elk1(ETS) 1e-27 29.83% 23.38% 
 
ETV1(ETS) 1e-26 71.38% 64.47% 
 
Elk4(ETS) 1e-25 29.16% 22.98% 
 
ELF5(ETS) 1e-25 54.18% 47.05% 
 
MYB(HTH) 1e-24 85.15% 79.66% 
 
ETS1(ETS) 1e-24 60.91% 54.00% 
 
Atf3(bZIP) 1e-23 52.34% 45.42% 
 
ERG(ETS) 1e-23 79.31% 73.38% 
 
ELF1(ETS) 1e-22 28.55% 22.74% 
 
BMYB(HTH) 1e-22 81.49% 75.88% 
 
AMYB(HTH) 1e-22 80.72% 75.09% 
 
PU.1(ETS) 1e-21 38.20% 31.91% 
 
EHF(ETS) 1e-20 75.46% 69.62% 
 
Fli1(ETS) 1e-20 59.57% 53.26% 
c) MPP-active enhancers 
Motif Name P-value Targets BG 
 
Fosl2(bZIP) 1e-99 35.76% 21.31% 
 
Fra1(bZIP) 1e-96 53.01% 36.97% 
 
Jun-AP1(bZIP) 1e-86 27.70% 15.57% 
 
Atf3(bZIP) 1e-85 58.03% 42.80% 
 
BATF(bZIP) 1e-81 56.96% 42.04% 
 
AP-1(bZIP) 1e-72 60.70% 46.68% 
 
Bach2(bZIP) 1e-50 20.65% 12.30% 
 
p53(p53) 1e-48 12.95% 6.59% 
 
p63(p53) 1e-43 35.25% 25.41% 
 
PU.1(ETS) 1e-34 42.55% 33.30% 
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GABPA(ETS) 1e-32 59.24% 49.93% 
 
ETS1(ETS) 1e-31 66.21% 57.19% 
 
Fli1(ETS) 1e-31 66.62% 57.63% 
 
ELF5(ETS) 1e-26 56.19% 47.77% 
 
ETV1(ETS) 1e-25 75.84% 68.44% 
 
EHF(ETS) 1e-24 77.24% 70.01% 
 
Bach1(bZIP) 1e-24 6.77% 3.47% 
 
SpiB(ETS) 1e-23 25.04% 18.67% 
 
Elk4(ETS) 1e-22 35.54% 28.38% 
 
NF-E2(bZIP) 1e-21 6.79% 3.62% 
 
ERG(ETS) 1e-21 82.17% 76.03% 
 
ELF1(ETS) 1e-20 34.62% 27.92% 
 
Elk1(ETS) 1e-20 35.54% 28.81% 
Table 5. Analysis of TFBS in epigenetically defined enhancers. Putative TFBS 
in cell-specific promoters and enhancers were identified using HOMER. Targets, 
percentage of query sequences that are motif enriched; BG, percentage of 
background sequences that are motif enriched.!
'
3.3.'Transcriptomic'analysis'of'HSPC'during'lineage'
commitment'
In order to define the promoter usage in HSPC and their committed 
progeny, we used CAGE sequencing, a technique that identifies active 
TSSs at single‐base-pair resolution and measures the expression level of 
each transcript, and applied a bioinformatics framework to identify clusters 
of transcription initiation events and classify them on the basis of annotated 
features and expression levels. 
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3.3.1.'Definition'of'whole'genome'high'resolution'map'of'
transcription'initiation'events'by'CAGE'sequencing'
3.3.1.1%CAGE%sequencing%mapping%statistics%and%single%nucleotide%
resolution%annotation%
We extracted total RNA from each cell population and generated CAGE tag 
libraries from the 5' ends of capped RNA PolII transcripts that were 
sequenced in separate Illumina lanes, generating a total of 33 millions 
reads of 29 bp in length that were then mapped to the human genome 
(hg19) using the rescue strategy of multimapped tag to improve the 
detection of TSSs [95]. This step resulted in an average mapping rate of 
40% producing a total of 13,439,976, of which 4,328,146, 4,695,128, and 
4,416,702 for HSPCs, EPPs, and MPPs respectively.  
We mapped more than 70% of the TSSs to promoters and 5’ UTRs of 
coding and non-coding genes in all cell types. Interestingly more than 20% 
of TSSs mapped to intergenic regions, introns, exons and 3’UTRs, 
supporting the hypothesis of the existence of alternative or novel promoters 
in hematopoietic progenitors. About 2% of TSSs mapped to the antisense 
strand of known genes, mostly in promoters and introns of coding 
transcripts, suggesting the presence of regulatory mechanisms involving 
antisense transcription (Figure 11). 
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Figure 11. Genomic distribution of CAGE TSSs in HSPC, EPP and MPP. TSSs 
were mapped to regions annotated as promoters, 5’ UTR, exon, intron and 3’ UTR of 
coding and noncoding genes (in sense or antisense orientation) or as intergenic 
regions. 
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3.3.1.2.%Promoter%identification%and%annotation%from%CAGEFseq%data%
In order to define transcriptional initiation regions, we clustered CAGE 
TSSs in promoters if they are within 20 bp of each other on the same 
chromosomal strand and have similar expression levels. Thus promoters 
are defined as local clusters of nearby and co-expressed TSSs. We 
identified similar numbers of promoters with comparable length distributions 
in the three cell types (Table 6). 
 
cell Tot median  Q1 (bp) Q3 (bp) 
HSPC 13.582 143 100 200 
EPP 14.041 143 99 201 
MPP 13.609 144 95 197 
Table 6. Statistics of promoters identified by CAGE TSSs clustering. Tot: 
number of promoters identified by CAGE; median, Q1 and Q3: median, first and 
third quantile of enriched regions length distributions. 
We then assigned CAGE promoters to the closest coding or non-coding 
transcript (including lincRNAs, miRNAs, rRNAss and snRNAs) using 
publicly available data sets. The majority (~80%) of them were annotated to 
known genes or transcripts in HSPCs (11,074 out of 13,852), EPPs (11,227 
out of 14,041) and MPPs (10,934 out of 13,609), and particularly to protein-
coding transcripts (69% in HSPCs and 70% in MPPs and EPPs). 
Interestingly, more than 2,600 promoters (~20%) were not associated with 
any known gene or transcript in all three cell types, and may drive 
transcription of yet unknown coding and non-coding transcripts (Figure 12). 
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Figure 12. Annotation of total and 
differentially used CAGE promoters. The 
graphs show the proportions of total and 
differentially used CAGE promoters 
associated to coding RNA and ncRNA 
(miRNA, rRNA, snoRNA and snRNAand 
lincRNA). 
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In order to identify the possible involvement of transposable elements in 
gene regulation, we assessed if CAGE promoters overlapped with 
annotated repeat masker categories from UCSC Genome Browser. We 
found that about 6% of all CAGE promoters overlapped with repetitive 
elements such as long interspersed elements (LINE), short interspersed 
elements (SINE) and long terminal repeat elements (LTR) (Figure 13).  
Figure 13. Genomic distribution of CAGE promoters in repetitive elements. 
CAGE promoters of HSPC, EPP and MPP were annotated with RepeatMasker 
regions. 
These results support the hypothesis that many of genes involved in the 
specification of HSPC cell fate may be regulated by transposable elements. 
'
3.3.2.'Quantitative'transcriptomic'analysis'of'HSPC'and'lineage@
restricted'progenitors'
3.3.2.1.%Differential%expression%analysis%of%CAGE%promoters%
In order to determine the differential promoter usage during erythroid and 
myeloid commitment, we applied a statistical method (edgeR) using read 
counts of CAGE promoters, adjusting the resulting p-values with Benjamini-
Hochberg correction. This analysis identified 725 differentially used 
promoters between HSPC and EPP, (265 down-regulated and 459 up-
regulated) and 1050 between HSPC and MPP (599 down-regulated and 
450 up-regulated). We looked at promoters that were specifically 
expressed in HSPC, and we found that only 77 promoters were expressed 
exclusively in HSPC and down-regulated in both EPP and MPP (“HSPC-
specific” promoters), while the remaining down-regulated promoters 
remained expressed in one of the two lineages (188 in EPP and 522 in 
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MPP). Of the up-regulated genes, 421 out of 459 were specific for EPP, 
and 412 out of 450 were up-regulated in MPP only. 
We then analysed the pathways involved in differentially expressed genes 
using DAVID [112]. Genes transcribed by HSPC-specific promoters were 
significantly enriched in functional categories related to multicellular 
organismal development, system development and immune response 
(modified Fisher’s Test EASE score ≤0.05 after Benjamini correction for 
multiple testing). Genes associated to EPP-specific promoters were 
enriched in hemoglobin pathway and erythrocyte development categories, 
while those associated to MPP-specific promoters were mainly involved in 
leukocyte biology and immune response. Conversely, promoters down-
regulated in EPP were associated with genes involved in immune response 
and leukocyte biology, while those down-regulated in MPP were associated 
to translation, structural constituent of ribosome, and macromolecular 
complex organization (Figure 14).  
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Figure 14. Functional annotation of genes associated to cell-specific 
promoters. Gene ontology analysis (DAVID 6.7) of genes associated with HSPC-, 
EPP- and MPP-specific CAGE promoters. 
 
We also found that a significant number of genes associated with CAGE 
promoters were functionally linked in cell-specific molecular networks, e.g., 
the DNA methyltransferase DNMT3A and CD34 pathways for HSPC-
specific and down-regulated promoters, and the GATA1 and CSF3R (G-
CSF receptor) pathways for EPP- and MPP-specific promoters, 
respectively.  
We next looked specifically at the set of differentially used promoters 
driving the expression of transcription factors (TFs), co-factors and 
chromatin remodelers. A few factors were over-expressed in HSPCs, such 
as the HSC regulators MYCN and DNMT3A, HOXA7, an essential TF in 
hematopoietic progenitors, SLA2, implicated in lymphocyte biology and 
NAP1L3 (nucleosome assembly protein 1-like 3), whose function in 
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hematopoiesis is yet unknown. EPP- and MPP-specific promoters drove 
the expression of known erythroid and myeloid transcriptional regulators, 
such as TAL1, GATA1, KLF1, NFE2, ZFPM1, LDB1, GFI1B, STAT5, MXI1 
and KLF3 in EPP, and NFIA, MNDA, LRRFIP1, ZBTB20, KLF4, NCOA4, 
STAT6, MEF2A, SREBF1, JARID2, MLL3 and MLLT10 in MPP. Along with 
these results we found that more than 50% of EPP- and MPP-specific TFs 
and co-factors were not previously associated to erythropoiesis or 
myelopoiesis, such as CREB3L3, EGR1, FBXO7, FHL2, HES6, SEC14L2, 
TEAD1, TSC22D1, TSC22D3, ZBTB16 in erythroid progenitors and 
ARID4A, ASH1L, BAZ2B, C21orf66, CNOT6, CREB5, DENND4A, FOS, 
GTF2A1, ID3, MXD4, NFIL3, NR2C1, REL, RREB1, SFRS14, SHPRH, 
TBC1D22A, ZBTB7B, ZNF587 and ZNF70 in myeloid progenitors. 
In order to assess if the different transcriptional programs could be possibly 
due to alternative promoter usage of genes we assessed if different CAGE 
promoters were assigned to the same gene (e.g. to different transcripts of 
the same gene), with different levels of expression between cell types. We 
observed lineage-specific alternative promoter usage only for six genes. As 
an example, the LMO2 gene, coding for a developmentally regulated 
transcription factor with a crucial role in haematopoietic development, is 
transcribed from three different promoters, of which Promoter 3 was active 
only in HSPCs, Promoter 1 mainly in HSPCs and MPPs, and Promoter 2 
essentially used by EPPs (Figure 15).  
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Figure 15. Example of alternative promoter usage. Three promoters of LMO2 
gene were differentially used in HSPC, EPP and MPP (Promoter 1, 2 and 3). The 
different promoters and their expression level (i.e. CAGE tag raw counts of each 
TSS) are shown. 
To better understand the regulatory circuitry operating on lineage-specific 
CAGE promoters, we analysed putative transcription factor binding sites 
(TFBS) within the proximal regions (-300 to +100 bp from TSSs) of 
differentially used promoters by HOMER tool [17]. HSPC-specific 
promoters were enriched for binding motifs of the ETS family of TFs, which 
regulate development and maintenance of HSCs and their differentiation 
along multiple lineages [105]. EPP- and MPP-specific promoters were 
instead enriched for motifs of ubiquitous promoter-associated TFs, like 
SP1, TBP, MAZ, NFY, NRF1, and lineage-specific TFs, such as GATA1, 
GATA2, TAL1, KLF1 and KLF4 for erythroid progenitors, and GABPA, 
FLI1, ETS1, ELK1, ELF1 and PU.1 for myeloid progenitors (Figure 16).  
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Figure 16. Analysis of putative TFBS within CAGE promoters. Transcription 
factor motif finding in cell-specific promoters was performed using HOMER 
software.  
Next, we analysed CAGE promoters not assigned to any known genes or 
transcripts. Around 22% of these unannotated promoters harboured an 
epigenetic enhancer signature, a value that increased up to 45% for DU 
promoters (Figure 17) suggesting that they may represent enhancer-
derived RNA acting in cis on adjacent target genes [113, 114]. 
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26.13% (16.37%), p < 10-8
Maz (Zf)
60.07% (47.94%), p < 10-8
ELF1 (ETS)
23.77% (14.74%), p < 10-7
NRF1
13.43% (6.91%), p < 10-7
PU.1 (ETS)
14.34% (7.70%), p < 10-7
MPP-specific CAGE promoters
Gata1 (Zf)
22.06% (5.76%), p < 10-27
Gata2 (Zf)
22.30% (6.35%), p < 10-25
GATA:SCL/TAL1
10.54% (1.31%), p < 10-24
Sp1 (Zf)
32.11% (18.96%), p < 10-9
TATA-Box (TBP)
25.74% (14.55%), p < 10-8
Klf4 (Zf)
22.30% (12.16%), p < 10-8
Maz (Zf)
62.99% (49.78%), p < 10-7
EKLF (Zf)
10.54% (4.51%), p < 10-6
ETS1 (ETS)
38.46% (19.76%), p < 10-3
Fli1 (ETS)
41.03% (22.82%), p < 10-3
ERG (ETS)
48.72% (29.80%), p < 10-3
GABPA (ETS)
33.33% (17.94%), p < 10-3
HSPC-specific CAGE promoters
EPP-specific CAGE promoters
E
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To analyse the influence of H3K27ac+ cell-specific enhancers on nearby 
genes, we analysed the expression level of the closest CAGE promoters 
taking the nearest neighbour gene to each enhancer. We observed a 
significant increase in gene expression compared to the whole set of 
promoters for all cell types (Figure 18), confirming that identified active 
enhancers are of striking importance in regulating transcriptional programs 
of HSPC in erythroid and myeloid commitment. 
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Figure 18. Effect of H3K27ac on nearest neighbor genes. TPM: 
tags per million mapped reads; *P<1e-10, Kolmogorov-Smirnov test. 
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Figure 17. Distribution of total and 
differentially used unannotated CAGE 
promoters overlapping with epigenetically 
defined promoters and enhancers.  
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3.4.'Chromatin'dynamics'at'cis@regulatory'elements'
We then examined the chromatin dynamics of HSPCs early commitment, 
by analysing histone marks enrichments at identified regulatory elements, 
such as developmental specific enhancers and differentially expressed 
promoters. Differentially expressed promoters showed between two 
condition showed non-specific enrichment in H3K4me3 and variable 
enrichment in H3K27ac that is dependent on the number of promoters 
being up-regulated in the examined conditions (Figure 19). 
 
 
Figure 19. Histone modification average enrichments at differentially 
expressed promoters.  
Conversely cell-specific active enhancers showed differential enrichment in 
histone marks during commitment. HSPC active enhancers showed high 
enrichment in H3K4me1 and H3K27ac at lower degree, while signal 
relative to EPP and MPP enhancers is absent. In erythroid and myeloid 
progenitors the situation was slightly different, showing specificity for 
H3K4me1 in EPP, while for MPP–specific active enhancers we noticed an 
enrichment of the same mark also in HSPC and EPP, but the presence of 
the H3K27ac mark was specific for myeloid commitment (Figure 20). 
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Figure 20. Histone modification average profile at lineage-specific active 
enhancers.  
These results showed that promoters were ubiquitously occupied by the 
same histone marks in different steps of HSPC early commitment, while 
enhancers are associated with active chromatin marks in a cell-type 
specific manner, thus acting a main role in erythroid and myeloid 
commitment. 
! '
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4.'CONCLUSIONS'AND'PERSPECTIVES'
As the last part of the dissertation, this section summarizes the results 
obtained in this study, suggesting future perspectives. 
Human hematopoietic stem cell-based therapy represents a real and 
potentially long−term cure for patients affected by hematological and 
oncological diseases. A better knowledge of HSC self-renewal, 
commitment and differentiation mechanisms is crucial to understand HSC 
biology and to develop HSC-based therapies. 
New high-throughput approaches based on the next-generation 
sequencing (NGS) technologies are essential to study the transcriptome, 
the epigenome and the usage of regulatory elements in the genome. In this 
study we used different high-throughput genome analysis tools, such as 
CAGE and ChIP-Seq, to define the transcriptional and epigenetic profile of 
cord blood-derived human hematopoietic stem/progenitor cells (HSPCs) 
and their committed erythroid and myeloid progeny, to characterize genes 
and regulatory regions fundamental in HPSC self-renewal, commitment 
and differentiation.  
We comprehensively analysed the transcriptome and the epigenome of 
CD34low/CD36high EPP and CD34low/CD13+ MPP cell populations, that 
represent earlier stages of erythroid and myeloid differentiation compared 
to the CD34-/CD36+/GYPA+ erythroid precursors and the CD14+ mature 
monocyte-macrophage elements analysed in previous studies [84, 115-
118].  
We used CAGE-seq analysis to define more than 13,000 transcriptionally 
active promoters in HSPC, EPP and MPP, the majority of which harboured 
an active (acetylated) epigenetic promoter signature. Our results showed 
that the three cell types shared most of the promoters and transcripts, 
suggesting that transcriptional states are largely maintained in early 
hematopoietic differentiation and progenitor identity during commitment is 
determined by a relatively small number of differentially used promoters. 
Moreover we showed that the differentially regulated fraction of promoters 
is significantly enriched in binding sites for transcription factors essential for 
hematopoietic development. CAGE and epigenetically defined strong 
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promoters overlapped in most cases, providing a robust signature for 
defining promoter usage. Interestingly, we identified only 77 promoters 
expressed exclusively in HSPCs and down-regulated in both EPPs and 
MPPs, while the remaining down-regulated promoters remained expressed 
in one of the two lineages. On the contrary, >95% of the 459 promoters up- 
regulated in EPPs and 450 up-regulated in MPPs were lineage-specific. 
These data indicate the existence of very few strictly HSPC-specific 
promoters and factors maintaining multilineage potential, and that lineage 
commitment is essentially exerted by up-regulation of a few hundred 
promoters, including those driving the expression of lineage-specific master 
TFs, such as TAL1, GATA1, KLF1, NFE2 and STAT5 in EPP, and NFIA, 
KLF4 and STAT6 in MPP.  
Analysis of histone modification signatures by ChIP-seq allowed the 
identification of more than 45,000 putative enhancers in each cell 
population, indicating that most promoters likely interact with multiple 
enhancers. Differently from promoters, enhancers consistently changed 
upon erythroid and myeloid commitment: about a half of the active, 
acetylated enhancers mapped in EPPs and MPPs were not shared with 
HSPC, while 75 and 90% of the active enhancers mapped in HSPCs 
disappeared in erythroid and myeloid commitment respectively. These data 
indicate that enhancers are dramatically redefined during lineage 
commitment, and that differential enhancer usage is responsible for the 
differential regulation of promoter activity underlying lineage restriction. 
Thus activation of the set of lineage-specific enhancers is most likely 
responsible for both activation of lineage-specific promoters and fine tuning 
of the non-specific ones. 
In conclusion, our data indicate that hematopoietic commitment and 
differentiation involve small changes of the transcriptional profile and 
"classical" promoter usage (CAGE and ChIP-Seq H3K4me3 data), and are 
mainly regulated by enhancers, which are differentially used in the specific 
lineages (as observed from CAGE and ChIP-Seq H3K4me1 data). 
Overall, we provided an overview of the differential transcriptional programs 
of HSPCs and committed myeloid and erythroid hematopoietic precursors. 
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Moreover, this study represents a unique source of genes and regulatory 
regions involved in HPSC self-renewal, commitment and differentiation. 
In the next future we will profile the action of lineage-specific transcription 
factors that were enriched in active enhancers and showed significant up-
regulation in erythroid or myeloid progenitors. Furthermore, chromatin 
conformation analyses, such as 5C and Hi-C, will be required to link active 
enhancers with their interacting promoters, in order to unveil the fine 
regulatory circuitry at the basis of HSPC erythroid and myeloid 
commitment. 
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6.'APPENDIX'
6.1.'Antibodies'used'for'FACS'analysis.'
Antibody Catalog # Company 
GpA-PE R7078 Dako 
GpA-APC 551336 BD Pharmingen 
CD11b-APC 553312 BD Pharmingen 
CD11b-FITC 553310 BD Pharmingen 
CD11b-pe 553311 BD Pharmingen 
CD33- APC 551378 BD Pharmingen 
CD13-PE MHCD1304 CALTAG 
CD34-FITC 345801 BD Pharmingen 
CD34-PE 345802 BD Pharmingen 
CD36-FITC 555454 BD Pharmingen 
CD38-APC 555462 BD Pharmingen 
CD71-PE IM2001U Beckman Coulter 
CD71 PerCP 551374 BD Pharmingen 
CD133/2(293C3)-PE 130-090-853 Miltenyi Biotech 
CD14-FITC 555393 BD Pharmingen 
!
6.2.'Differentially'expressed'genes'in'erythroid'commitment'detected'
by'microarray'analysis.'
Gene  Gene Name FC P value 
HBBP1 hemoglobin, beta pseudogene 1 8.03 0.000001 
HBB hemoglobin, beta 7.42 0.000046 
HBE1 hemoglobin, epsilon 1 7.26 0.000506 
CD36 CD36 molecule (thrombospondin receptor) 6.73 0.000005 
RHAG Rh-associated glycoprotein 6.32 0.000011 
CNRIP1 cannabinoid receptor interacting protein 1 6.28 0.005413 
TUBB2A tubulin, beta 2A 6.20 0.000044 
NMU neuromedin U 6.17 0.001302 
XK X-linked Kx blood group (McLeod syndrome) 6.13 0.000027 
ERAF erythroid associated factor 5.85 0.000640 
KLF1 Kruppel-like factor 1 (erythroid) 5.40 0.000265 
PF4 platelet factor 4 5.28 0.003868 
APOC1 apolipoprotein C-I 5.03 0.000018 
EPB42 erythrocyte membrane protein band 4.2 5.00 0.001048 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), 
member 2 4.94 0.000124 
S100A8 S100 calcium binding protein A8 4.90 0.010992 
SPTA1 spectrin, alpha, erythrocytic 1 (elliptocytosis 2) 4.85 0.000068 
TMEM56 transmembrane protein 56 4.85 0.002134 
HBD hemoglobin, delta 4.75 0.010117 
CA2 carbonic anhydrase II 4.72 0.004686 
ITGA2B integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa 
complex, antigen CD41) 4.49 0.000020 
TIMP3 TIMP metallopeptidase inhibitor 3 4.46 0.000087 
SLC6A8 solute carrier family 6 (neurotransmitter transporter, 
creatine), member 8 4.45 0.006580 
IRF6 interferon regulatory factor 6 4.37 0.002134 
KEL Kell blood group, metallo-endopeptidase 4.36 0.000011 
TSC22D3 TSC22 domain family, member 3 4.35 0.001438 
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Gene  Gene Name FC P value 
PRG2 proteoglycan 2, bone marrow (natural killer cell activator, 
eosinophil granule major basic protein) 4.32 0.004047 
ANK1 ankyrin 1, erythrocytic 4.28 0.000031 
ALAS2 aminolevulinate, delta-, synthase 2 4.27 0.002038 
PKLR pyruvate kinase, liver and RBC 4.24 0.001943 
RFESD Rieske (Fe-S) domain containing 4.18 0.000068 
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 4.16 0.000007 
PNMT phenylethanolamine N-methyltransferase 4.14 0.002940 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 4.05 0.000001 
DHRS3 dehydrogenase/reductase (SDR family) member 3 4.03 0.004707 
GATA1 GATA binding protein 1 (globin transcription factor 1) 4.03 0.000503 
BLVRB biliverdin reductase B (flavin reductase (NADPH)) 4.03 0.000495 
PROS1 protein S (alpha) 4.00 0.000575 
FAM132B family with sequence similarity 132, member B 3.99 0.000600 
CHST2 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 3.98 0.000200 
DDIT4 DNA-damage-inducible transcript 4 3.95 0.000967 
YPEL4 yippee-like 4 (Drosophila) 3.94 0.000002 
GAD1 glutamate decarboxylase 1 (brain, 67kDa) 3.90 0.003131 
ALOX5 arachidonate 5-lipoxygenase 3.87 0.002718 
CLC Charcot-Leyden crystal protein 3.79 0.043636 
ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood 
group) 3.78 0.000346 
MYO1D myosin ID 3.77 0.006220 
SEPT10 septin 10 3.75 0.000025 
TRIB2 tribbles homolog 2 (Drosophila) 3.73 0.000017 
CD24 CD24 molecule 3.73 0.046025 
TSPAN6 tetraspanin 6 3.62 0.000025 
PMP22 peripheral myelin protein 22 3.49 0.001247 
GYPA glycophorin A (MNS blood group) 3.47 0.009992 
ALAS1 aminolevulinate, delta-, synthase 1 3.46 0.000010 
HBZ hemoglobin, zeta 3.45 0.001038 
FAM171A1 family with sequence similarity 171, member A1 3.44 0.002002 
ATP7B ATPase, Cu++ transporting, beta polypeptide 3.44 0.000590 
APOE apolipoprotein E 3.44 0.019903 
OSBPL6 oxysterol binding protein-like 6 3.37 0.002182 
TUBB1 tubulin, beta 1 3.37 0.007354 
JAZF1 JAZF zinc finger 1 3.36 0.000144 
PPEF1 protein phosphatase, EF-hand calcium binding domain 1 3.36 0.017919 
FAM178B family with sequence similarity 178, member B 3.35 0.019388 
NDFIP2 Nedd4 family interacting protein 2 3.34 0.000012 
GNAQ guanine nucleotide binding protein (G protein), q polypeptide 3.33 0.000058 
TMOD1 tropomodulin 1 3.30 0.000143 
PKM2 pyruvate kinase, muscle 3.30 0.001942 
HES6 hairy and enhancer of split 6 (Drosophila) 3.28 0.001757 
ZFPM1 zinc finger protein, multitype 1 3.28 0.000246 
LXN latexin 3.27 0.000968 
CLCN4 chloride channel 4 3.27 0.000001 
CMTM5 CKLF-like MARVEL transmembrane domain containing 5 3.26 0.005450 
LEPR leptin receptor 3.22 0.002566 
HBM hemoglobin, mu 3.18 0.002604 
C2orf88 chromosome 2 open reading frame 88 3.12 0.001122 
CBS cystathionine-beta-synthase 3.07 0.005707 
PLK1 polo-like kinase 1 (Drosophila) 3.04 0.001060 
ADFP adipose differentiation-related protein 3.03 0.000006 
LOC388588 hypothetical LOC388588 3.01 0.000884 
EPB49 erythrocyte membrane protein band 4.9 (dematin) 3.01 0.002203 
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GFI1B growth factor independent 1B transcription repressor 3.01 0.000122 
G0S2 G0/G1switch 2 3.00 0.000113 
AQP1 aquaporin 1 (Colton blood group) 2.99 0.002404 
IL2RG interleukin 2 receptor, gamma (severe combined 
immunodeficiency) 2.98 0.008690 
NUCB1 nucleobindin 1 2.98 0.000366 
IL2RA interleukin 2 receptor, alpha 2.97 0.000043 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 2.94 0.000083 
RTN1 reticulon 1 2.92 0.038727 
MUC1 mucin 1, cell surface associated 2.91 0.000299 
HBQ1 hemoglobin, theta 1 2.90 0.000007 
FKBP5 FK506 binding protein 5 2.88 0.000086 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 2.87 0.005637 
LMNA lamin A/C 2.86 0.000179 
WFDC1 WAP four-disulfide core domain 1 2.85 0.014183 
KLHDC8B kelch domain containing 8B 2.84 0.002207 
TUBB2B tubulin, beta 2B 2.82 0.010122 
SLC16A9 solute carrier family 16, member 9 (monocarboxylic acid 
transporter 9) 2.82 0.041530 
LMAN1 lectin, mannose-binding, 1 2.82 0.001399 
PBK PDZ binding kinase 2.80 0.000088 
PDLIM1 PDZ and LIM domain 1 2.80 0.000875 
PPAP2A phosphatidic acid phosphatase type 2A 2.79 0.001531 
TFR2 transferrin receptor 2 2.79 0.003792 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 2.79 0.006862 
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase) 2.79 0.011459 
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) 2.78 0.003071 
P4HA2 prolyl 4-hydroxylase, alpha polypeptide II 2.78 0.000507 
ITGAM integrin, alpha M (complement component 3 receptor 3 
subunit) 2.78 0.020347 
ADD2 adducin 2 (beta) 2.77 0.001392 
SH2D2A SH2 domain protein 2A 2.76 0.031300 
RGS16 regulator of G-protein signaling 16 2.75 0.002007 
EPS8 epidermal growth factor receptor pathway substrate 8 2.75 0.005551 
LOX lysyl oxidase 2.74 0.030823 
GTF2I general transcription factor II, i 2.71 0.000070 
REPS2 RALBP1 associated Eps domain containing 2 2.71 0.000129 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 2.71 0.020271 
ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 2.70 0.000164 
FHL2 four and a half LIM domains 2 2.69 0.000124 
CAST calpastatin 2.68 0.000004 
FZD3 frizzled homolog 3 (Drosophila) 2.68 0.001500 
GSTM3 glutathione S-transferase mu 3 (brain) 2.67 0.022365 
NCKAP1 NCK-associated protein 1 2.67 0.000688 
DARC Duffy blood group, chemokine receptor 2.66 0.000131 
TRAPPC1 trafficking protein particle complex 1 2.66 0.000743 
PLD3 phospholipase D family, member 3 2.66 0.001067 
COL18A1 collagen, type XVIII, alpha 1 2.65 0.000027 
BCL2L11 BCL2-like 11 (apoptosis facilitator) 2.63 0.000600 
ARL4A ADP-ribosylation factor-like 4A 2.63 0.000777 
TLE1 transducin-like enhancer of split 1 (E(sp1) homolog, 
Drosophila) 2.62 0.001484 
C20orf108 chromosome 20 open reading frame 108 2.62 0.000031 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 2.59 0.000123 
HDHD3 haloacid dehalogenase-like hydrolase domain containing 3 2.57 0.002685 
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PARVB parvin, beta 2.57 0.000260 
ADORA2B adenosine A2b receptor 2.56 0.006139 
THBS1 thrombospondin 1 2.54 0.010131 
TPM1 tropomyosin 1 (alpha) 2.52 0.001261 
C17orf99 chromosome 17 open reading frame 99 2.52 0.009234 
SLAMF1 signaling lymphocytic activation molecule family member 1 2.51 0.038275 
KLF9 Kruppel-like factor 9 2.50 0.001700 
MPP1 membrane protein, palmitoylated 1, 55kDa 2.50 0.000033 
ANKRD57 ankyrin repeat domain 57 2.49 0.001585 
ALOX5AP arachidonate 5-lipoxygenase-activating protein 2.49 0.002462 
AMMECR1 Alport syndrome, mental retardation, midface hypoplasia and 
elliptocytosis chromosomal region gene 1 2.48 0.000003 
G6PD glucose-6-phosphate dehydrogenase 2.48 0.000878 
EMP3 epithelial membrane protein 3 2.47 0.000081 
C1orf150 chromosome 1 open reading frame 150 2.46 0.018192 
ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 2.46 0.007024 
ERRFI1 ERBB receptor feedback inhibitor 1 2.43 0.039253 
CD46 CD46 molecule, complement regulatory protein 2.43 0.002322 
S100A10 S100 calcium binding protein A10 2.41 0.000162 
HIPK3 homeodomain interacting protein kinase 3 2.41 0.000970 
TNIK TRAF2 and NCK interacting kinase 2.40 0.000191 
IL9R interleukin 9 receptor 2.40 0.000143 
ALDH6A1 aldehyde dehydrogenase 6 family, member A1 2.40 0.006546 
CTSH cathepsin H 2.40 0.018772 
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 2.39 0.026085 
STON1 stonin 1 2.39 0.006653 
NCOA2 nuclear receptor coactivator 2 2.39 0.000103 
ALAD aminolevulinate, delta-, dehydratase 2.38 0.017645 
FREQ frequenin homolog (Drosophila) 2.38 0.002354 
ALDOC aldolase C, fructose-bisphosphate 2.38 0.040266 
MAN1A1 mannosidase, alpha, class 1A, member 1 2.35 0.000176 
TXNIP thioredoxin interacting protein 2.34 0.001908 
CCNA1 cyclin A1 2.33 0.007367 
C19orf59 chromosome 19 open reading frame 59 2.33 0.036549 
GAS2L1 growth arrest-specific 2 like 1 2.33 0.000389 
EPAS1 endothelial PAS domain protein 1 2.32 0.000629 
LRP11 low density lipoprotein receptor-related protein 11 2.32 0.000364 
PRKAB1 protein kinase, AMP-activated, beta 1 non-catalytic subunit 2.32 0.005656 
ERMAP erythroblast membrane-associated protein (Scianna blood 
group) 2.30 0.000591 
REEP3 receptor accessory protein 3 2.29 0.001283 
ATP8B1 ATPase, class I, type 8B, member 1 2.28 0.049081 
PRKCSH protein kinase C substrate 80K-H 2.28 0.000032 
IGFBP2 insulin-like growth factor binding protein 2, 36kDa 2.27 0.002099 
TPSAB1 tryptase alpha/beta 1 2.26 0.017475 
VEGFA vascular endothelial growth factor A 2.25 0.007244 
GEM GTP binding protein overexpressed in skeletal muscle 2.25 0.004995 
H1F0 H1 histone family, member 0 2.25 0.002134 
IL1RL1 interleukin 1 receptor-like 1 2.24 0.016679 
UBXN10 UBX domain protein 10 2.22 0.001364 
MTSS1 metastasis suppressor 1 2.22 0.000029 
S100A6 S100 calcium binding protein A6 2.21 0.000172 
EPCAM epithelial cell adhesion molecule 2.21 0.009886 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A 2.21 0.000168 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 2.20 0.000160 
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PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 2.20 0.000685 
WBP2 WW domain binding protein 2 2.20 0.000066 
SLC24A3 solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 3 2.20 0.018555 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 2.19 0.021642 
SNAP23 synaptosomal-associated protein, 23kDa 2.19 0.004031 
RARRES1 retinoic acid receptor responder (tazarotene induced) 1 2.18 0.010656 
C13orf15 chromosome 13 open reading frame 15 2.18 0.009746 
RTN2 reticulon 2 2.18 0.000990 
CD37 CD37 molecule 2.18 0.001087 
FYN FYN oncogene related to SRC, FGR, YES 2.17 0.011288 
ZNF192 zinc finger protein 192 2.17 0.002480 
WNK3 WNK lysine deficient protein kinase 3 2.17 0.041102 
ANKRD37 ankyrin repeat domain 37 2.16 0.001488 
AKAP12 A kinase (PRKA) anchor protein 12 2.16 0.021380 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase) 2.16 0.000362 
SLC25A37 solute carrier family 25, member 37 2.15 0.014699 
P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 2.15 0.008397 
ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 2.15 0.000093 
ABHD14B abhydrolase domain containing 14B 2.14 0.000417 
BHLHE40 basic helix-loop-helix family, member e40 2.14 0.001208 
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 
(lysophosphatidic acid acyltransferase, alpha) 2.14 0.000011 
SLC44A2 solute carrier family 44, member 2 2.14 0.002525 
LCN2 lipocalin 2 2.13 0.006845 
TPST2 tyrosylprotein sulfotransferase 2 2.13 0.000207 
CAMK1 calcium/calmodulin-dependent protein kinase I 2.11 0.001968 
SOCS1 suppressor of cytokine signaling 1 2.11 0.000003 
MAZ MYC-associated zinc finger protein (purine-binding 
transcription factor) 2.11 0.007220 
APOBEC3C apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3C 2.10 0.000087 
EREG epiregulin 2.09 0.037605 
PIR pirin (iron-binding nuclear protein) 2.09 0.002241 
TIMP1 TIMP metallopeptidase inhibitor 1 2.09 0.008648 
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4 2.09 0.000373 
FECH ferrochelatase (protoporphyria) 2.09 0.001234 
MYRIP myosin VIIA and Rab interacting protein 2.08 0.021268 
PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma 2.08 0.006428 
LOC541471 hypothetical LOC541471 2.07 0.000435 
STXBP6 syntaxin binding protein 6 (amisyn) 2.07 0.004146 
NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha 2.06 0.000412 
TMEM214 transmembrane protein 214 2.05 0.012853 
CPA3 carboxypeptidase A3 (mast cell) 2.05 0.001252 
GALC galactosylceramidase 2.05 0.000110 
RAB6B RAB6B, member RAS oncogene family 2.04 0.019713 
PDZD8 PDZ domain containing 8 2.04 0.003795 
FRAT1 frequently rearranged in advanced T-cell lymphomas 2.04 0.002574 
ENSG000001
83700 
NA 2.04 0.002810 
ADAM10 ADAM metallopeptidase domain 10 2.04 0.002900 
BSG basigin (Ok blood group) 2.04 0.000181 
ELL2 elongation factor, RNA polymerase II, 2 2.03 0.000372 
MOSPD3 motile sperm domain containing 3 2.03 0.000089 
IL10RA interleukin 10 receptor, alpha 2.03 0.014880 
FHDC1 FH2 domain containing 1 2.02 0.009671 
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LPAR5 lysophosphatidic acid receptor 5 2.02 0.002706 
SLC4A2 solute carrier family 4, anion exchanger, member 2 
(erythrocyte membrane protein band 3-like 1) 2.01 0.001793 
TAL1 T-cell acute lymphocytic leukemia 1 2.00 0.000340 
TARDBP TAR DNA binding protein -2.00 0.000083 
TMEM163 transmembrane protein 163 -2.01 0.017745 
FSTL1 follistatin-like 1 -2.01 0.002255 
SLC22A4 solute carrier family 22 (organic cation/ergothioneine 
transporter), member 4 -2.01 0.001119 
SGK3 serum/glucocorticoid regulated kinase family, member 3 -2.01 0.002213 
CORO1A coronin, actin binding protein, 1A -2.01 0.000244 
CD34 CD34 molecule -2.02 0.013742 
RSPH10B2 radial spoke head 10 homolog B2 (Chlamydomonas) -2.02 0.000832 
BEX5 brain expressed, X-linked 5 -2.02 0.001639 
RHOBTB1 Rho-related BTB domain containing 1 -2.03 0.021154 
IFI16 interferon, gamma-inducible protein 16 -2.04 0.014353 
P2RY8 purinergic receptor P2Y, G-protein coupled, 8 -2.04 0.003957 
STYK1 serine/threonine/tyrosine kinase 1 -2.04 0.010581 
ZNF573 zinc finger protein 573 -2.04 0.047831 
BAX BCL2-associated X protein -2.04 0.002302 
SIDT1 SID1 transmembrane family, member 1 -2.05 0.000065 
PABPC4L poly(A) binding protein, cytoplasmic 4-like -2.05 0.000015 
SNX10 sorting nexin 10 -2.06 0.000125 
NSUN6 NOL1/NOP2/Sun domain family, member 6 -2.06 0.000316 
DNAJC17 DnaJ (Hsp40) homolog, subfamily C, member 17 -2.06 0.000093 
SH3TC1 SH3 domain and tetratricopeptide repeats 1 -2.07 0.001603 
NRIP3 nuclear receptor interacting protein 3 -2.07 0.001599 
PSTPIP1 proline-serine-threonine phosphatase interacting protein 1 -2.07 0.002279 
ALCAM activated leukocyte cell adhesion molecule -2.08 0.015837 
S100Z S100 calcium binding protein Z -2.08 0.000753 
ZC3H12D zinc finger CCCH-type containing 12D -2.08 0.009060 
SOX4 SRY (sex determining region Y)-box 4 -2.08 0.000171 
ATL1 atlastin GTPase 1 -2.08 0.000343 
BEX2 brain expressed X-linked 2 -2.09 0.017168 
NUTF2 nuclear transport factor 2 -2.09 0.014930 
ASGR1 asialoglycoprotein receptor 1 -2.11 0.000220 
CERK ceramide kinase -2.12 0.000077 
FAM43A family with sequence similarity 43, member A -2.13 0.001233 
RGS19 regulator of G-protein signaling 19 -2.13 0.002537 
KIAA1841 KIAA1841 -2.15 0.001256 
PRAGMIN homolog of rat pragma of Rnd2 -2.15 0.005921 
GARNL4 GTPase activating Rap/RanGAP domain-like 4 -2.15 0.003128 
CLEC5A C-type lectin domain family 5, member A -2.16 0.045442 
DSE dermatan sulfate epimerase -2.18 0.007097 
BAT2D1 BAT2 domain containing 1 -2.20 0.002105 
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) -2.20 0.000256 
HERC5 hect domain and RLD 5 -2.20 0.003103 
PHGDH phosphoglycerate dehydrogenase -2.21 0.001139 
CASP1 caspase 1, apoptosis-related cysteine peptidase (interleukin 
1, beta, convertase) -2.21 0.043319 
ANPEP alanyl (membrane) aminopeptidase -2.21 0.001708 
ATP9A ATPase, class II, type 9A -2.22 0.007067 
PRRT3 proline-rich transmembrane protein 3 -2.24 0.000155 
FAM111B family with sequence similarity 111, member B -2.26 0.000053 
MGC29506 hypothetical protein MGC29506 -2.27 0.002300 
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GPR183 G protein-coupled receptor 183 -2.27 0.020849 
ZBTB8A zinc finger and BTB domain containing 8A -2.28 0.008525 
TRBV27 T cell receptor beta variable 27 -2.28 0.014474 
AMICA1 adhesion molecule, interacts with CXADR antigen 1 -2.28 0.022934 
RAB27A RAB27A, member RAS oncogene family -2.28 0.000178 
CACHD1 cache domain containing 1 -2.29 0.000312 
MALAT1 metastasis associated lung adenocarcinoma transcript 1 
(non-protein coding) -2.30 0.000390 
CCDC58 coiled-coil domain containing 58 -2.31 0.006058 
CHST13 carbohydrate (chondroitin 4) sulfotransferase 13 -2.31 0.004531 
C9orf91 chromosome 9 open reading frame 91 -2.31 0.002074 
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 -2.32 0.001674 
FNBP1 formin binding protein 1 -2.34 0.000009 
ZNF738 zinc finger protein 738 -2.35 0.000664 
RTP4 receptor (chemosensory) transporter protein 4 -2.36 0.000586 
ZNF662 zinc finger protein 662 -2.37 0.000716 
GAPT GRB2-binding adaptor protein, transmembrane -2.37 0.001412 
RNASE3 ribonuclease, RNase A family, 3 (eosinophil cationic protein) -2.38 0.000573 
ZNF257 zinc finger protein 257 -2.38 0.000433 
NKG7 natural killer cell group 7 sequence -2.39 0.011124 
DLK1 delta-like 1 homolog (Drosophila) -2.40 0.009290 
C12orf75 chromosome 12 open reading frame 75 -2.43 0.005260 
GPX7 glutathione peroxidase 7 -2.44 0.004387 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) -2.44 0.004600 
ZNF492 zinc finger protein 492 -2.46 0.005513 
IL17D interleukin 17D -2.48 0.002180 
CPNE2 copine II -2.48 0.007568 
C1orf228 chromosome 1 open reading frame 228 -2.49 0.001539 
GPR124 G protein-coupled receptor 124 -2.49 0.001546 
C9orf43 chromosome 9 open reading frame 43 -2.50 0.000034 
TMSB15A thymosin beta 15a -2.50 0.010245 
EMP1 epithelial membrane protein 1 -2.52 0.001110 
MDFIC MyoD family inhibitor domain containing -2.53 0.000534 
NPDC1 neural proliferation, differentiation and control, 1 -2.53 0.001252 
C1orf59 chromosome 1 open reading frame 59 -2.54 0.000001 
ANKRD36B ankyrin repeat domain 36B -2.54 0.008665 
IGHM immunoglobulin heavy constant mu -2.54 0.001262 
ERG v-ets erythroblastosis virus E26 oncogene homolog (avian) -2.57 0.001374 
LOXL1 lysyl oxidase-like 1 -2.58 0.000676 
NLRC3 NLR family, CARD domain containing 3 -2.58 0.002137 
CYYR1 cysteine/tyrosine-rich 1 -2.58 0.014357 
IL12RB2 interleukin 12 receptor, beta 2 -2.59 0.000866 
FAM26F family with sequence similarity 26, member F -2.59 0.016239 
HOXA5 homeobox A5 -2.59 0.004721 
DUSP4 dual specificity phosphatase 4 -2.59 0.000923 
CD93 CD93 molecule -2.59 0.004464 
TIMP2 TIMP metallopeptidase inhibitor 2 -2.62 0.034073 
HSF5 heat shock transcription factor family member 5 -2.63 0.000349 
ZNF439 zinc finger protein 439 -2.63 0.004860 
HOXA7 homeobox A7 -2.64 0.000106 
TMEM71 transmembrane protein 71 -2.64 0.005164 
LOC729680 hypothetical protein LOC729680 -2.64 0.001055 
GPR84 G protein-coupled receptor 84 -2.65 0.000016 
LOC643332 similar to Nonsecretory ribonuclease precursor 
(Ribonuclease US) (Eosinophil-derived neurotoxin) (RNase 
UpI-2) (Ribonuclease 2) (RNase 2) 
-2.65 0.000513 
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RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-
regulated) -2.65 0.001957 
RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-
regulated) -2.71 0.000106 
BZRAP1 benzodiazapine receptor (peripheral) associated protein 1 -2.72 0.000001 
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase) -2.73 0.004048 
CRHBP corticotropin releasing hormone binding protein -2.73 0.000679 
LMNB1 lamin B1 -2.73 0.000000 
PION pigeon homolog (Drosophila) -2.74 0.000029 
CALN1 calneuron 1 -2.76 0.000036 
ARMCX1 armadillo repeat containing, X-linked 1 -2.77 0.005759 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa -2.79 0.017261 
HOXA9 homeobox A9 -2.80 0.012864 
IFITM1 interferon induced transmembrane protein 1 (9-27) -2.80 0.034237 
SPNS3 spinster homolog 3 (Drosophila) -2.81 0.010428 
TCTEX1D1 Tctex1 domain containing 1 -2.82 0.003789 
FAM169A family with sequence similarity 169, member A -2.86 0.000835 
MSRB3 methionine sulfoxide reductase B3 -2.87 0.004449 
PXDN peroxidasin homolog (Drosophila) -2.90 0.000035 
SH3BP4 SH3-domain binding protein 4 -2.92 0.000822 
TRIM22 tripartite motif-containing 22 -2.92 0.001888 
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3) -2.93 0.001155 
LTB lymphotoxin beta (TNF superfamily, member 3) -2.94 0.000258 
TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 -2.95 0.013789 
DNLZ DNL-type zinc finger -2.96 0.000696 
GIMAP7 GTPase, IMAP family member 7 -2.97 0.002201 
ATP8B4 ATPase, class I, type 8B, member 4 -3.02 0.001027 
SUCNR1 succinate receptor 1 -3.08 0.000456 
PRAM1 PML-RARA regulated adaptor molecule 1 -3.08 0.019985 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 -3.10 0.011381 
CD200 CD200 molecule -3.14 0.000074 
NEURL1B neuralized homolog 1B (Drosophila) -3.15 0.000005 
TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68kDa -3.17 0.001031 
MN1 meningioma (disrupted in balanced translocation) 1 -3.17 0.002195 
SLC22A16 solute carrier family 22 (organic cation/carnitine transporter), 
member 16 -3.18 0.000327 
GOLGA9P golgi autoantigen, golgin subfamily a, 9 pseudogene -3.18 0.001387 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid 
transporter 14) -3.22 0.000915 
KBTBD11 kelch repeat and BTB (POZ) domain containing 11 -3.27 0.000051 
PLEKHO1 pleckstrin homology domain containing, family O member 1 -3.30 0.000034 
CXCR7 chemokine (C-X-C motif) receptor 7 -3.31 0.000253 
C5orf23 chromosome 5 open reading frame 23 -3.31 0.007896 
KIAA1274 KIAA1274 -3.31 0.000006 
NPR3 natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) -3.33 0.000049 
C12orf5 chromosome 12 open reading frame 5 -3.37 0.004099 
GLIPR1 GLI pathogenesis-related 1 -3.38 0.002403 
CXorf21 chromosome X open reading frame 21 -3.39 0.000638 
CTHRC1 collagen triple helix repeat containing 1 -3.41 0.000054 
ENSG000001
67912 
NA -3.43 0.000122 
TMEM200A transmembrane protein 200A -3.46 0.000652 
DUSP6 dual specificity phosphatase 6 -3.47 0.001800 
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IFI44 interferon-induced protein 44 -3.48 0.004774 
CTSG cathepsin G -3.48 0.002935 
MIRHG2 microRNA host gene 2 (non-protein coding) -3.52 0.000059 
SCHIP1 schwannomin interacting protein 1 -3.58 0.000015 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) -3.59 0.000648 
TFEC transcription factor EC -3.63 0.000013 
SORL1 sortilin-related receptor, L(DLR class) A repeats-containing -3.72 0.004780 
LOC284422 similar to HSPC323 -3.78 0.000569 
MPO myeloperoxidase -3.84 0.024036 
MT-ND6 mitochondrially encoded NADH dehydrogenase 6 -3.87 0.000014 
HLF hepatic leukemia factor -3.88 0.002206 
MYO5C myosin VC -3.89 0.000000 
LY75 lymphocyte antigen 75 -3.94 0.000002 
SELL selectin L -3.97 0.000034 
ARMCX2 armadillo repeat containing, X-linked 2 -3.97 0.000015 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b -3.98 0.000784 
AIM1 absent in melanoma 1 -4.02 0.014656 
PTPRCAP protein tyrosine phosphatase, receptor type, C-associated 
protein -4.04 0.001413 
RGL4 ral guanine nucleotide dissociation stimulator-like 4 -4.12 0.000677 
CTSZ cathepsin Z -4.18 0.000173 
BAALC brain and acute leukemia, cytoplasmic -4.49 0.000148 
CHRDL1 chordin-like 1 -4.58 0.000011 
UBTD2 ubiquitin domain containing 2 -4.59 0.000104 
PROM1 prominin 1 -4.82 0.010952 
C1QTNF4 C1q and tumor necrosis factor related protein 4 -4.96 0.001387 
NOG noggin -5.06 0.001137 
SPINK2 serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin 
inhibitor) -6.73 0.000456 
 
6.3.'Differentially'expressed'genes'in'myeloid'commitment.'
Gene  Gene Name FC P value 
S100A8 S100 calcium binding protein A8 6.91 0.000007 
PRTN3 proteinase 3 5.78 0.000368 
ELANE elastase, neutrophil expressed 5.41 0.006886 
CLC Charcot-Leyden crystal protein 4.67 0.018955 
AZU1 azurocidin 1 4.57 0.000465 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 3.94 0.003005 
CD24 CD24 molecule 3.91 0.000881 
S100A9 S100 calcium binding protein A9 3.88 0.001064 
ALOX5 arachidonate 5-lipoxygenase 3.85 0.011731 
VCAN versican 3.77 0.001689 
SLPI secretory leukocyte peptidase inhibitor 3.71 0.001067 
HBB hemoglobin, beta 3.68 0.005643 
C19orf59 chromosome 19 open reading frame 59 3.58 0.000217 
PRG2 proteoglycan 2, bone marrow (natural killer cell activator, 
eosinophil granule major basic protein) 3.54 0.015258 
MNDA myeloid cell nuclear differentiation antigen 3.49 0.000992 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 3.43 0.003291 
SERPINB10 serpin peptidase inhibitor, clade B (ovalbumin), member 10 3.43 0.000376 
CSTA cystatin A (stefin A) 3.36 0.000171 
CST7 cystatin F (leukocystatin) 3.35 0.000170 
STON1 stonin 1 3.34 0.000823 
HP haptoglobin 3.34 0.000556 
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C5orf20 chromosome 5 open reading frame 20 3.30 0.000751 
MS4A3 membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) 3.20 0.007733 
CFD complement factor D (adipsin) 3.07 0.004227 
S100P S100 calcium binding protein P 3.03 0.006748 
NCF2 neutrophil cytosolic factor 2 3.00 0.002454 
RETN resistin 2.94 0.001154 
HCK hemopoietic cell kinase 2.89 0.000786 
CD1D CD1d molecule 2.81 0.005186 
RAB20 RAB20, member RAS oncogene family 2.80 0.000007 
PIWIL4 piwi-like 4 (Drosophila) 2.79 0.002774 
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 2.72 0.002343 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 2.69 0.002087 
LOC283663 hypothetical LOC283663 2.69 0.007697 
LYZ lysozyme (renal amyloidosis) 2.62 0.002217 
ADAMDEC1 ADAM-like, decysin 1 2.61 0.011886 
CNRIP1 cannabinoid receptor interacting protein 1 2.60 0.020620 
ANXA3 annexin A3 2.60 0.000589 
PARP8 poly (ADP-ribose) polymerase family, member 8 2.54 0.000548 
HAL histidine ammonia-lyase 2.53 0.000282 
LIN7A lin-7 homolog A (C. elegans) 2.50 0.003810 
EGID-79948 plasticity-related gene 2 2.50 0.000003 
CTSG cathepsin G 2.47 0.000223 
ELOVL3 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 3 2.46 0.009838 
S100A12 S100 calcium binding protein A12 2.44 0.012070 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.44 0.009607 
P2RY13 purinergic receptor P2Y, G-protein coupled, 13 2.43 0.000658 
CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 2.43 0.012363 
PLBD1 phospholipase B domain containing 1 2.39 0.029536 
OLR1 oxidized low density lipoprotein (lectin-like) receptor 1 2.33 0.048440 
CLEC12A C-type lectin domain family 12, member A 2.33 0.003719 
SLC22A15 solute carrier family 22, member 15 2.32 0.000013 
CD14 CD14 molecule 2.31 0.003414 
DYSF dysferlin, limb girdle muscular dystrophy 2B (autosomal 
recessive) 2.28 0.001532 
TGFBI transforming growth factor, beta-induced, 68kDa 2.28 0.009135 
ASGR2 asialoglycoprotein receptor 2 2.27 0.000117 
NAPSB napsin B aspartic peptidase pseudogene 2.27 0.000762 
MPEG1 macrophage expressed 1 2.26 0.005274 
LRG1 leucine-rich alpha-2-glycoprotein 1 2.24 0.004884 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide 2.22 0.002326 
CD36 CD36 molecule (thrombospondin receptor) 2.22 0.000078 
BEX1 brain expressed, X-linked 1 2.22 0.044141 
IPCEF1 interaction protein for cytohesin exchange factors 1 2.21 0.007888 
FZD2 frizzled homolog 2 (Drosophila) 2.21 0.021064 
TCN1 transcobalamin I (vitamin B12 binding protein, R binder 
family) 2.20 0.049048 
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 
(non-specific cross reacting antigen) 2.20 0.022493 
C12orf59 chromosome 12 open reading frame 59 2.18 0.004136 
RNASE2 ribonuclease, RNase A family, 2 (liver, eosinophil-derived 
neurotoxin) 2.16 0.000946 
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene 
homolog 2.13 0.000647 
CLU clusterin 2.13 0.005949 
! 89!
Gene  Gene Name FC P value 
GPR160 G protein-coupled receptor 160 2.12 0.002806 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), 
member 2 2.12 0.008066 
ALOX5AP arachidonate 5-lipoxygenase-activating protein 2.12 0.002995 
LY86 lymphocyte antigen 86 2.11 0.003033 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.11 0.002477 
TYROBP TYRO protein tyrosine kinase binding protein 2.10 0.000550 
ACPP acid phosphatase, prostate 2.09 0.000879 
ALAS1 aminolevulinate, delta-, synthase 1 2.06 0.000194 
RNASE6 ribonuclease, RNase A family, k6 2.06 0.000505 
FCN1 ficolin (collagen/fibrinogen domain containing) 1 2.02 0.010237 
SEPP1 selenoprotein P, plasma, 1 2.01 0.000268 
SLC47A1 solute carrier family 47, member 1 2.01 0.002740 
PCOLCE2 procollagen C-endopeptidase enhancer 2 2.00 0.001528 
ALOX12 arachidonate 12-lipoxygenase 2.00 0.004849 
CILP2 cartilage intermediate layer protein 2 2.00 0.001953 
CXCR7 chemokine (C-X-C motif) receptor 7 -2.02 0.003424 
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 -2.05 0.005281 
TMEFF1 transmembrane protein with EGF-like and two follistatin-like 
domains 1 -2.09 0.000108 
CALN1 calneuron 1 -2.10 0.000011 
SMAGP small trans-membrane and glycosylated protein -2.10 0.000038 
EMP1 epithelial membrane protein 1 -2.10 0.006898 
FAM111B family with sequence similarity 111, member B -2.16 0.011623 
RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-
regulated) -2.16 0.001808 
PLCB4 phospholipase C, beta 4 -2.17 0.000004 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 -2.18 0.000195 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) -2.19 0.009220 
NPR3 natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) -2.24 0.000253 
GNAI1 guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 1 -2.27 0.000131 
KIAA0125 KIAA0125 -2.27 0.000239 
IL12RB2 interleukin 12 receptor, beta 2 -2.34 0.000333 
CHRDL1 chordin-like 1 -2.34 0.001850 
NAP1L3 nucleosome assembly protein 1-like 3 -2.36 0.001473 
CD34 CD34 molecule -2.38 0.000183 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 -2.41 0.000056 
TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 -2.43 0.000365 
CTHRC1 collagen triple helix repeat containing 1 -2.43 0.000037 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 -2.46 0.004316 
HTR1F 5-hydroxytryptamine (serotonin) receptor 1F -2.47 0.000132 
C5orf23 chromosome 5 open reading frame 23 -2.53 0.000016 
RAI14 retinoic acid induced 14 -2.53 0.000382 
GBP1 guanylate binding protein 1, interferon-inducible, 67kDa -2.69 0.017717 
HEMGN hemogen -2.74 0.000021 
AKR1C3 aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II) -2.79 0.010452 
GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3) -2.84 0.001536 
IFI44 interferon-induced protein 44 -2.86 0.000719 
CNN3 calponin 3, acidic -2.97 0.000004 
SPINK2 serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin 
inhibitor) -3.00 0.000094 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid 
transporter 14) -3.07 0.001477 
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MMRN1 multimerin 1 -3.09 0.000266 
CRHBP corticotropin releasing hormone binding protein -3.25 0.000809 
BEX2 brain expressed X-linked 2 -3.26 0.000961 
HLF hepatic leukemia factor -3.30 0.002439 
TMSB15A thymosin beta 15a -3.37 0.007020 
ARMCX2 armadillo repeat containing, X-linked 2 -3.52 0.000017 
TMEM200A transmembrane protein 200A -3.55 0.000282 
DLK1 delta-like 1 homolog (Drosophila) -3.96 0.000169 
 
6.4.'Lists'of'promoters'
Complete lists of promoters identified using CAGE-seq are available at 
http://www.webcitation.org/6ZBVNp55l 
6.5.'Lists'of'active'enhancers'
Complete lists of active enhancers identified using ChIP-seq are available at 
http://www.webcitation.org/6ZBVNp55l 
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